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Abstract
Cancer metastasis is a multistep process that begins with the invasion of tumour cells into the
stroma and migration towards the blood vessels. Tumour cells that have entered the
bloodstream must then survive and leave by a process known as extravasation. Finally,
extravasated cells proliferate and establish the secondary site in the metastatic cascade.
Although extravasation encompasses key events during cancer cell invasion to aid in the
development of effective treatments, an in vivo model that rapidly, reproducibly and
economically recapitulates cancer cell extravasation is needed. Therefore, the objectives of my
research were to 1) establish and validate an in vivo model of cancer cell extravasation, and 2)
identify novel cellular and molecular events.
I used the chorioallantoic membrane of chicken embryos as a model system of extravasation
as it provides an accessible and highly vascularized structure. The combination of the
chorioallantoic membrane of chicken embryos, nanoscale flow cytometry, and confocal
microscopy-based intravital imaging allowed me to observe that extravasating prostate cancer
cells exhibited significant cell volume reduction. This reduction is suggestive of an invasive
cell phenotype. However, cell volume reduction at certain threshold also decreased cancer cell
extravasation efficiency. I also found that cancer cell released extracellular vesicles during
extravasation, and an increase in extracellular vesicle release caused cell volume reduction. I
then tested the hypothesis that extracellular vesicle release and extravasation may be linked to
modes of cell death. Real-time imaging of cancer cells that released extracellular vesicles
during extravasation did not show activation of caspase-3. Activation of necroptosis, however,
increased extracellular vesicle release and decreased cell extravasation and secondary colony
formation. These results suggest that necroptosis may be targeted to induce extracellular
vesicle release, decrease extravasation, and halt cancer metastasis.
Collectively, my work lays out the protocols for the use of the chorioallantoic membrane of
chicken embryos as a model system to investigate cancer cell extravasation and invasion. Use
of this model system allowed me to identify extracellular vesicle release during extravasation
and discover that necroptosis may be a potential regulator of cancer metastasis.
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Summary for Lay Audience
Cancer spreading to different areas in the body is known as metastasis and is the main cause
of cancer-related deaths. Many underlying events in cancer metastasis are still poorly
understood. To provide new insights, I first established a new model to study metastasis. I
injected human prostate cancer cells into the blood vessel of chicken embryo lungs. I then
monitored the cancer cells in real-time using microscopy. This technique was optimized, and
results were published to allow other researchers to study metastasis in this quick, economical,
and reliable model. For the second part of my part, I investigated the changes that take place
in cancer cells when the cells move from the injected area to different areas. I observed that
cancer cells shrink their sizes when they move out of the blood stream to enter different sites.
My results also indicate that this shrinking of cancer cells may have been made possible by a
release of small portions of the cell. I reasoned that if this release can be artificially increased,
it would possibly kill more cancer cells and provide a new target to stop metastasis. Indeed,
my results show that increasing the release of cell portions reduces the ability of cancer cells
to move to secondary sites. Therefore, my studies lay the foundation for a new therapeutic
target for cancer patients.

Keywords
Cancer metastasis, chorioallantoic membrane, metastatic cascade, extravasation,
invadopodia, extracellular vesicle, necroptosis, RIPK3, MLKL
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Chapter 1

1

Introduction

1.1 Underlying cellular process during cancer metastasis
1.1.1

Dogma of cancer metastasis

Cancer is an extremely heterogeneous disease. There are more than 200 different cancer
types1. However, certain cellular and molecular events are shared between these various
cancer types, and are termed the hallmarks of cancer2. Advances in basic scientific research
have identified therapeutic targets in many different cancers, which alone, or in
combination have yielded promising initial results3. Unfortunately, despite these advances,
many patients still succumb to cancer recurrence and relapse.
Metastasis is a critical event in cancer progression, contributing to over 90% mortality in
cancer patients4. Metastasis and its level, inform the stage of cancers and provide
information on the survival chance of patients. The most invasive cancers (for example,
triple negative breast cancer, kidney cancer, prostate cancer, and melanomas) metastasize
to several distant organs or tissues such as the bone, liver, brain, and lungs5. This movement
of cancer cells from the primary site to a secondary site is a multistep process termed the
metastatic cascade6. Accumulation of genetic mutations and changes to the tissue
microenvironment facilitates cell transformation, uncontrollable cell growth and
proliferation, and establishment of the primary tumour2. As the primary tumour confronts
microenvironmental stresses such as changes in oxygen and nutrient levels, pH, growth
factors, chemokines and cytokines, cells in the tumour assume an invasive phenotype to
find secondary growth sites and maintain their proliferation2,6,7. Alteration of metastasis
suppressor genes plays a significant role in these processes8–11. For example, highly
metastatic murine K-1735 melanoma cells exhibit reduced NM23 gene expression and
form metastases in rats12.
Once cancer cells migrate to secondary organs, the stroma at these sites provides a
sustainable niche that allows tumour cells to adapt and proliferate. Certain cancers migrate
towards specific secondary organs to form colonies, according to the Paget’s “seed and
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soil” theory (Table 1)13. For example, breast and prostate cancer cells preferably
metastasize to the bone. It is believed that processes at these secondary sites may facilitate
homing of the cancer cells. In the case of bones, bone remodeling secretes chemokines,
growth factors, and angiogenic factors that may facilitate breast and prostate cancer
secondary colony formation14. However, certain cancers such as brain, pancreatic, and
ovarian cancers do not exhibit bone metastases15. Instead, pancreatic and ovarian cancer
metastasize to peritoneum, a site not assaulted by breast and prostate cancer.
Heterogeneity in metastatic potential and intensity may also exist within the cancer type.
Therefore, cancer metastasis varies in origin, underlying molecular process, intensity of
the spread, and secondary site. In addition, since invasive tumours can utilize different
molecular pathways to succeed in metastasis, clear understanding of each molecular
mechanism is required to develop multiple therapeutic strategies to halt both localized and
metastasized tumours.

3

Cancer Type

Primary Site

Principal Site of Metastasis

Breast Cancer

Breast

Bone, lung, liver, and brain

Small Cell Carcinoma

Lung

Brain, liver and bone

Malignant Melanoma

Skin

Lung, brain and liver

Prostate Cancer

Prostate

Bone

Testicular Cancer

Tastis

Liver

Colorectal Cancer

Colon/rectum

Liver and lung

Neuroblastoma

Mediastinum/abdomen

Liver

Table 1: Tumour type specific metastatic sites based on Paget's "seed and soil"
theory13
Table is reproduced here for educational purpose only and not for any commercial use.
Table is included in the Ph.D. dissertation with attribution13

1.1.2

Limits of current therapeutics targeting metastatic cancers

Currently, chemotherapy is commonly used with radiation or hormonal therapy after
surgery to target localized and metastasized tumours. However, most chemotherapeutic
agents show general cytotoxicity16,17. This cytotoxicity is partially due to high doses of
chemotherapeutic drugs that are needed to contain cancer growth. Cells within the tumour
respond to anti-cancer drugs differently, necessitating a high dose18. Most primary tumours
comprise highly heterogenous cells. Chromosomal instability in cancer cells causes
somatic mutagenesis and epigenetic heterogeneity. Metastatic cancers adopt genetic and
epigenetic alterations allowing some subpopulations of cancer cells to resist anti-cancer
drugs and grow after drug treatment is stopped19. Tumour cells may also acquire intrinsic
resistance to cytotoxic chemoradiotherapies20. Numerous metastatic cancers (for example,
colorectal cancer and breast cancer) show lower levels of reactive oxygen species
production and the activation of ataxia telangiectasia mutated (ATM)-dependent DNA-
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damage repair process to escape chemotherapy-induced changes. Furthermore, many
cancers can develop multidrug resistance by repelling chemotherapeutic agents out and
impairing drug delivery21. Therefore, understanding the underlying cellular and molecular
processes involved in cancer metastasis may provide novel avenues to develop effective
and fast-acting therapies.

1.1.3

The metastatic cascade

Cancer becomes life-threatening by spreading to different organs throughout successive
steps of the metastatic cascade6,22,23. Throughout this sequence, cancer cells confront
pressures that they must overcome. Initially, cancer growth is contained at the primary site.
Acquisition of invasive phenotypes allows cancer cells to migrate towards blood or
lymphatic conduits. Degradation of vessel basement membranes and migration across the
endothelial lining allow the cells access to other tissues. Cancer cells now must survive the
circulation, stall in small capillaries, cross the endothelial lining, and establish a metastatic
colony in secondary organs.
Cancer cells generate hypoxic regions that induce endothelial cell migration and
proliferation24. Hypoxic environment is kin to the activation of the hypoxia-inducible
factor (HIF) pathway25. Cancer cells in hypoxic regions increase the expressions of
angiogenic and hematopoietic growth factors such as vascular endothelial growth factor
(VEGF)26. Elevated local VEGF and other angiogenic factors increase endothelial cell
permeability, migration, and proliferation. The increase in vascular permeability and
density may facilitate cancer cells to intravasate into the bloodstream27. The newly formed
blood vessels in tumours are highly atypical, tortuous, and may lack directional blood flow.
These abnormal vessels also reduce pH and increase interstitial fluid pressure, which
hamper immune cell functions and allow cancer cells to escape through leaky vessels28,29.

5

Figure 1: The metastatic cascade comprises local invasion, intravasation,
hematogenous migration, extravasation, and metastatic colony formation30. (A)
Cancer cells acquire an invasive phenotype by undergoing epithelial-to-mesenchymal
transition (EMT). This transition allows cancer cells to become motile by losing epithelium
characteristics such as E-cadherin. (B) Cancer cells with an invasive phenotype intravasate
through the leaky blood vessels and begin their journey in the circulation. (C) Cancer cells
migrate across the circulatory system during that cells confront shearing forces, immune
surveillance, and cell death. (D) Cancer cells arrest in small blood vessels such as
capillaries at secondary sites and extravasate into the stromal space. (E) Extravasated
cancer cells either survive or undergo cell deaths. Surviving cancer cells can also then
continue their proliferation or become dormant. (F) A secondary metastatic colony is
formed when a permissive microenvironment allows surviving cancer cells to proliferate.
Figure is reproduced here for educational purpose only and not for any commercial use.
Figure is included in the Ph.D. dissertation with attribution30.

The migration of cancer cells from the primary site (intravasation) requires morphological
changes that allow cancer cells to become invasive and migratory (Figure 1A, B). This
phenotypic change manifests as cytoskeleton rearrangement, loss of apical-basal polarity,
and acquisition of a mesenchymal phenotype (termed epithelial-to-mesenchymal transition
(EMT)) (Figure 1A). Apical-basal polarity is a hallmark of epithelial cells, and is mainly
regulated by epithelial cadherin (E-cadherin) and cytokeratin31. E-cadherin and cytokeratin
facilitate tight junctions, adherens junctions, gap junctions, and assembling desmosomes.
Cancer cells receive extracellular cell- and tissue-specific stimulating factors to induce the
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activation of several genes involved in motility and intravasation. An increase of
transforming growth factor- (TGF-) expression leads to the activation of downstream
colony stimulating factor 1 receptor (CSF1R), among other proteins. CSF1R is involved in
cellular motility and the inhibition of CSF1R has been shown to reduce cancer cell motility
and intravasation in vivo32. CSF1R also suppresses keratins and claudins, which are
involved in a reduction of cancer cell invasion and intravasation33. TGF- also activates
LIM/homeobox protein (LHX2), which enhances cancer cell intravasation and
metastasis32,34. The expression of epidermal growth factor receptor (EGFR; Erb2 and Erb3)
on cancer cells also affects the level of cancer cell invasiveness and intravasation 35.
Although EGFR is mainly involved in stimulating tumour growth, overexpression of
EGFR induces intravasation by phosphoinositide 3-kinase (PI3K) and neural WiskottAldrich syndrome protein (N-WASP) that induce invadopodia formation36. Loss of Ecadherin and expression of mesenchymal genes such as N-cadherin, fibronectin, and
vimentin37, facilitate disassembly of cytoskeleton anchored to desmosomes, allowing the
cancer cells to form invadopodia and become motile. As a result, cancer cells can proceed
to intravasation and enter the circulation.
Intravasated cells, termed circulating tumour cells (CTCs), migrate along the circulatory
system before lodging/stalling at the capillaries of secondary sites (Figure 1C)38. CTCs
confront an extremely stressful extracellular milieu consisting of innate immune system,
oxidative stress, and shear forces from blood pressure39,40. In this environment, only about
0.1% of CTCs survive to attempt colony formation at secondary sites41. To avoid innate
immune system-mediated attacks, CTCs can attach to platelets and myeloid cells, and
avoid circulating immune cells. In addition, CTCs associate with fibrin to anchor to the
blood vessel endothelium, which allows the cells to escape into the stroma before immune
cells mount an attack42,43. Primary tumours may also release clusters of cells that form
microemboli. Such microemboli formation can lead to local metastatic foci and increase
metastatic efficiency44.
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Perhaps a key determinant of metastatic spread is extravasation. Although most single
tumour cells extravasate into the stroma first and proliferate later, some tumour cells may
also proliferate in the blood vessel before extravasating45. It is plausible that tumour
proliferation in circulation is an attempt to increase the frequency of extravasation or
likelihood of survival of extravasating cells. Increased expression of endothelial adhesion
molecules such as integrins facilitates adherence of CTCs to endothelial cells. Tumour cells
may also get support from platelets to adhere to the endothelium via 3 integrin
interaction46,47. Studies have shown that a3 integrins on MDA-MB-435 cells increase the
expression of matrix metallopeptidase 9 (MMP9) resulting in more migration and
metastatic foci in the lungs48,49. Combination of TGF- and a3 also prevents anoikis of
tumour cells50. Tumour cell-activated platelets also release dense granule-derived ATP
which modulates endothelial junctions and creates spaces that allow cancer cells to
transmigrate51. As tumour cells arrive at the secondary sites, a mesenchymal-epithelial
transition (MET) takes place52–54. A recent study documented histological evidence of an
epithelial phenotype of metastases, which was similar to the primary tumour55,56.
Cytoskeletal changes that accompany MET allow cancer cells to recruit granulocytes (for
example, neutrophils) by building a chemoattractant gradient comprised of CXCL5 and
CXCL757,58. CXCL5 and CXCL7 bind to CXCR2 chemokine receptors on neutrophils at
the sites of extravasation. Once neutrophils detect circulating tumour cells, neutrophils
form neutrophil extracellular traps (NETs) by degranulating to sequester tumour cells59. In
this process, 1 integrins can help tumour cells attach to the endothelium and MMP-9
secreted by neutrophils can degrade the endothelial basement membrane barrier so that
tumour cells can pass through. Tumour cells also release CC-chemokine ligand 2 (CCL2)
that binds to CC-chemokine receptor 2 (CCR2) of Ly6C-positive circulating monocytes.
Recruited monocytes differentiate into metastasis-associated macrophages (MAMs) that
release VEGF to increase the permeability of the blood vessels60,61. In addition, tumour
cells can secret VEGF themselves to induce further endothelial leakiness, promoting
tumour cell extravasation62. Tumour cells can also enhance extravasation by secreting
angiopoietin-like 4 (ANGPTL4)/C-terminal fibrinogen-like domain (cANGPTL4) that
loosens the tension of vascular endothelium and tight junctions63. Secreted cANGPTL4
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can temporarily interact with 51, vascular endothelial-cadherin, and clautin-5 that help
facilitate metastasis64.
Most cancer cell extravasation (Figure 1D) is paracellular migration wherein tumour cells
pass through endothelial cells. However, tumour cells can also pass through individual cell
bodies by a process called transcellular migration65,66,67. Extravasation appears to be
challenging due to more restricted endothelium of mature blood vessels near distant organs.
However, single tumor cells from the primary tumor generally undergo intravasation easily
due to malformed and irregular tumor blood vessels exhibiting loss of endothelium and
disrupted cell junctions29. To facilitate extravasation, tumour cells form finger like
protrusive structures termed invadopodia that are rich in actin and degrade the extracellular
matrix36,66. Invadopodia formation is a highly coordinated process due to the involvement
of multi-regulatory proteins. Tumour cells form invadopodia by responding to growth
factors and extracellular matrix-mediated integrin signalling. Upon receiving stimulating
signals, actin regulatory proteins (N-WASP, cortactin, and ARP2/3) facilitate local F-actin
nucleation68. TKS4 and TKS5, other regulatory and adaptor proteins, are also involved in
invadopodia formation and maturation. Cancer cell invadopodia mainly facilitate the
degradation of extracellular matrix23,68.
Tumour cells that enter the stroma of secondary sites need to survive, enter dormancy or
undergo cell death6 (Figure 1E, F). Tissues rich in growth promoting factors (TGF-,
insulin-like growth-factor-1) such as bones and breast can provide sustainable nutrient-rich
environment to tumour cells69. The presence of specific growth factor receptors can also
affect tumour cell metastatic efficiency. EGFR on colon and other cancer cells can respond
to transforming growth factor- (TGF-) from the liver that helps cancer cells adapt to the
liver environment and facilitate metastatic growth70,71. Lastly, tumour cells can change
gene-expression patterns in response to organ-specific microenvironment. Human renal
cell carcinoma KG-2 cells implanted in the kidney of athymic nude mouse form both local
tumours and metastases in the lungs, whereas KG-2 cells implanted subcutaneously only
form local tumours72. Associated with this behaviour, KG-2 cells implanted in the kidney
showed significantly higher expression of urokinase-type plasminogen activator (u-PA)
compared to KG-2 cells implanted subcutaneously72.
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1.1.4

Cancer extravasation is a realistic target to combat cancer
metastasis

Emerging studies on cancer extravasation have highlighted its significance in the metastatic
cascade. Extravasation is not only limited to transendothelial migration of leukocytes and
cancer cells but represents quite a common biological process. In cancer progression,
however, extravasation is a crucial step. Only a very small number of disseminated cancer
cells end up forming metastatic colonies in experimental metastasis assays6. In vivo assays
show that only 10% of extravasated B16F10 melanoma cells successfully formed
secondary colonies in vivo73. Therefore, it appears that extravasation is a rate-limiting step
in the metastatic cascade. Many potential drugs targeting invadopodia formation in
invasive cancer cells are under development. As outlined above, morphological changes in
cancer cells facilitate extravasation through invadopodia formation66,74,75. Invadopodia
formation and maturation are regulated by several proteins which include TKS4 and TKS5.
A previous study showed that impaired invadopodia formation throughout siRNAmediated TKS4 and TKS5 knockdown resulted in the abrogation of breast cancer cell
extravasation and cancer cell colony formation in mouse lungs66. Studies also show that
Src kinase regulates invadopodia biogenesis in extravasating cancer cells by interacting
with cortactin and F-actin74,76. Bowden et al. and Mader et al. demonstrated enhanced
invadopodia formation upon constitutive Src expression, and decreased invadopodia
formation and degradation of ECM upon Src knockdown in human breast cancer MDAMB-231 cells77,78. SU6656, a Src inhibitor, significantly reduced invadopodia formation,
migration, and metastatic colony formation in MDA-MB-231 cells74. It is not surprising
that studies on invadopodia inhibition have flourished recently, and various potential
therapeutics are being tested for evidence of extravasation inhibition.
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1.1.5

Animal model systems for studying cancer metastasis

Identification of cellular and molecular mechanisms underlying cancer cell extravasation
is dependent on appropriate in vivo models. In vitro culture studies on cancer migration or
invasion offer an economical and versatile assessment of metastatic potential. Cancer cells
with genetic modification/chemical treatment can be cultured and monitored readily and
offer valuable information. However, all observations made in these in vitro studies need
to be validated in in vivo models. In addition to offering a more realistic context, cancer
cells spreading to preferred sites can also be investigated in in vivo systems. Currently, in
vivo metastasis models include non-mammalian and mammalian systems. Select systems
will be discussed here.

1.1.6

Non-mammalian models

Dictyostelium discoideum and Caenorhabditis elegans are useful models to study cancer
chemotaxis and invasion79. D. discoideum shows amoeboid migration towards cAMP.
Interaction between cAMP and cAMP receptor (cAR1) polarizes and prepares cells to
migrate through G and G79,80. D. discoideum shows not only a transient increase in cell
polarity upon uniform chemoattractant stimulation, but also a persistent and spatially
restricted increase in cell polarity in response to a chemoattractant gradient.
C. elegans is a simple model of basement membrane invasion. It has a very unique body
component called the single cell that breaches two underlying basement membranes81. The
single cell can form an anchor, similar to invadopodia, which is formed by FOS-1A82
activation. Zinc metalloprotease 1 (ZMP-1), downstream of FOS-1A, degrades basement
membranes83,84. These non-mammalian models are certainly valuable in providing
mechanistic insights into specific cellular events such as protrusive structure formation
which may be similar to cancer cell invasion and metastasis.

11

1.1.7

Mouse models of metastasis

The mouse model has become the gold standard in cancer research85 and offers multiple
advantages. Gene homology between human and mouse allows investigators to study
cancer metastasis in mouse cell lines derived from carcinogen-induced tumours,
spontaneous tumours, or normal cells that are transformed in culture86. Cancer cells
implanted to create syngeneic and xenograft models of the cancer87. Implanting human
cancer cells and tissues is also widely used88. However, there may be species differences
that may limit the biological significance of some findings.
One of the advantages of using the mouse model is that it provides an appropriate
context/microenvironment to the tumour cells to study primary tumour growth, assess
metastasis, and tropism. Experimental models in which cancer cells are injected into blood
vessels allow researchers to monitor cell extravasation and metastatic colony formation88.
The different means of administering cancer cells have been recently reviewed by Khanna
and Hunter89. Cancer cells can be injected into the lateral tail vein, portal vein, carotid
artery, and left ventricle of the heart. Of these, tail vein injection is the most common route
to administer cancer cells and reliably generates lung metastases. Intracardiac injection is
used to study bone and brain metastasis. In this case, cancer cells are injected into the left
ventricle of the heart. Depending on the cancer type introduced, intracardiac injection can
allow cancer cells to spread through most organs in the body. However, breast and prostate
cancer metastases are mainly found in the bone from the intracardiac injection. Intra-portal
or intrasplenic injection directly introduces cancer cells into the liver.
Metastasis models are designed to examine the metastatic cascade but do not provide
information on primary tumour growth and intravasation88. To overcome this limit, cancer
cells or tissues can be transplanted ectopically or orthotopically to create spontaneous
metastasis model. These models allow rapid tumour growth under the skin which is highly
vascularized and tumour growth can be easily measured by calipers88. Orthotopic
transplantation is also suitable to examine initial phases of the metastatic cascade as
tumours are generated at the original primary tumour sites88.
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Cancer cells that are introduced in mice may be compromised by the host immune system.
Immunodeficient mice such as athymic nude mice and severe combined immunodeficient
(SCID) mice can resolve the host immune system issue90,91. Although these mice are
deficient in the adaptive immune system, endogenous innate immunity still remains.
However, these mice models are expensive and labour-intensive, require several high-level
techniques including surgical skills, injections, and restraint techniques. Therefore, animal
models that are easy, reliable, cost-effective, high-throughput, and allow modulation of
genes and testing of potential treatments are needed.

1.1.8

Chorioallantoic membrane (CAM) of avian embryo
metastasis model.

The chorioallantoic membrane (CAM) of avian embryos is not a new/recent model. It has
been utilized as a cancer xenograft model for almost a hundred years92. In 1912,
transplantation of mouse and rat tumours on the CAM of chicken embryo showed not only
tumour growths but identified tumours that were passed from eggs to eggs92. Advantages
of utilizing the CAM in cancer research are mostly due to the structure of the CAM. Avian
embryos utilize the CAM as the respiratory organ to exchange oxygen and carbon dioxide.
The CAM shows a highly vascularized structure and a fully developed lymphatic system
that have similar functions and molecular compositions as the mammalian system93.
Histological examination of the CAM shows the presence of two epithelial layers and a
thin layer of stroma in between. Chicken embryos cultured ex ovo expose the CAM to the
outside so that the structure provides easy access to the vasculature. Because of this open
structure, researchers may use the CAM model to study the development of the vasculature.
It only takes 6-7 days for the development of vasculature94. The accessibility and short
period of development make the CAM model easier to handle compared to the mouse
model. Although it was reported that the CAM has a slow development of non-specific
immune system from day 15 onwards, the system is still naturally immunodeficient
compared to the mouse model95. Another advantage of the CAM of chicken embryo is that
it is cost-effective and overcomes the inadequacy of power in studies. In addition, CAM
allows investigators to perform a high-throughput screen.

13

Xenografts of several cancer cell lines and tumour tissues successfully grow on the
CAM96,97,98,99,100. Klingenberg et al. reported that xenografts of the Burkitt lymphoma cell
lines BL2B95 on the CAM of day 10 chicken embryos exhibited growth101. Histological
examination confirmed the establishment of the tumour. Transmission electron
microscopy-based imaging also highlighted tumour structures and infiltrating granulocytes
and macrophages. Immunofluorescence labeling in the CAM showed BL2B95 cells
forming tumours and lymphatic metastases. Time-lapse imaging of the CAM also showed
the spreading of BL2B95 cells to distant sites.
Dr. Ann F. Chambers’ group102 modified the CAM assay in 1980s to study metastasis.
Instead of creating an ex ovo model, top of eggshell was removed by drilling and cancer
cells were injected intravenously into the CAM of day 11 chicken embryos 103. Since then,
the metastatic efficiency of different cancer cells have been evaluated in the CAM assay
by monitoring survival and homing of injected cancer cells104. Studies also have assessed
vascular permeability of the CAM with various sizes of dextrans and intravital imaging.
Pink et al. showed that the rates of 158-kDa TRITC-dextran leakage were higher in nontumour tissue, tumour tissue, and necrotic core sites, compared to the rates of 2000-kDa
FITC-dextran105. In addition, CAMs, which were exposed to VEGF, showed more leakage
of doxorubicin105. This study shows that the vascular permeability of the CAM can be
modulated, which is valuable in studies of cancer extravasation. There are still a number
of unanswered questions, such as inherent blood vessel permeability of different ages of
chicken embryos. There is a need to further characterize and optimize the experimental
CAM metastasis model.

1.2 Cancer cell extracellular vesicle biogenesis and
potential roles in cancer metastasis
1.2.1

The biogenesis and roles of extracellular vesicles

In 1967, Dr. Peter Wolf discovered platelet extracellular vesicles (EVs) as platelet dust
encapsulated in lipid-rich transmembrane106. These structures were still able to perform a
biological activity, anticoagulation in plasma and serum106. Since then, research on these
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cell dust particles has centered around characterizing which cell types generate them and
what their biological roles are. EV is a collective term which is used to describe
heterogenous membrane vesicles, and includes exosomes, microparticles, and apoptotic
bodies. It is now known that the content of EV cargoes is decided by the releasing cells.
The physiological and pathological states that induce EV release are also being
characterized.
Exosomes are derived from the maturation of multivesicular bodies (MVB) and secreted
by exocytosis107. Exosomes are smaller (50-100 nm in diameter) compared to plasma
membrane-derived vesicles termed microparticles/ectosomes (greater than 100nm and over
1μm)108,109. Exosomes participate in intercellular communication in both normal and
pathological states. Maturation process of MVB plays a key role in exosome biogenesis,
by generating intraluminal vesicles (ILVs). ILVs are generated by the inward budding and
fission of limiting late endosomal membrane. Resulted ILVs are carried by the endosomal
sorting complexes required for transport (ESCRT) machinery comprising of ESCRT-II and
III. The ESCRT complex with the ESCRT-III subunit, vacuolar protein sorting-associated
protein 32 (VPS32), makes contact between ILV and programmed cell death 6-interacting
protein (ALIX). Later ILVs undergo fusion with the cell surface and secretion by
exocytosis108,109.

Stein and Luzio in 1991 found that neutrophils shed vesicles embraced by isotope labelledcellular plasma membrane lipids through ectocytosis110. Larger EVs (microparticles,
ectosomes) are released when cells are activated by intra- and/or extra-cellular stimuli and
initiate cytoskeletal remodeling. Endocytosis and cargo recycling may also initiate large
EV biogenesis with the help of ADP-ribosylation factor 6 (ARF6). Several cytoskeletal
remodeling-associated small GTPases, such as ARF6, activate phospholipase D (PLD) and
extracellular signal-regulated kinase (ERK), allowing for the formation and shedding of
membrane blebs75,111,112. RhoA and RHO-associated protein kinase (ROCK) are other
important regulators of actin organization and microparticle biogenesis. ROCK,
downstream from RhoA, activates Lim kinase-cofilin which is involved in the formation
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of plasma membrane derived microparticles113. In addition to the cytoskeletal remodeling
by ARF6, cytosolic Ca2+ levels are involved in microparticle biogenesis. Changes in
cytosolic Ca2+ levels activate aminophospholipid translocases (flippases and floppases),
scramblases and calpain, which then regulate plasma membrane phospholipid asymmetry.
The asymmetry of phospholipids allows the plasma membrane to undergo restructuring of
actin cytoskeleton, leading to the plasma membrane blebbing and microparticle release114.
Inhibiting scramblases suppresses phosphatidylserine exposure (PS) on blood platelets and
reduces microparticle production115. Microparticle release also consists of several regulator
proteins including ARF6 and ATPase VPS4. ARF6 phosphorylates myosin light chain
(MLC) that induces actomyosin contraction followed by shedding microparticles from the
plasma membrane. VPS4 induces scission of microparticles derived from the interaction
between arrestin domain-containing protein-1 and tumour susceptibility gene 101
(TSG101) on the plasma membrane116. Lastly, microparticle release can be initiated in a
ATP-dependant manner by P2X7 receptors maneuvering rearrangement of the plasma
membrane117,118.
One of the most significant findings in EV research is the discovery of EV-specific protein
markers119. Similar to cell body, EVs are encapsulated by fatty acids constituting the
plasma membrane: EV membrane is enriched in sphingomyelin, PS, cholesterol, and
saturated fatty acids. However, outer EV membrane is more PS-rich compared to cell
plasma membrane. This somewhat unique feature has implicated PS as a potential EV
surface marker. EVs also inherit many of the surface and cytosolic proteins of the cells
from where they originate. Advanced techniques such as ultracentrifugation of the EVs and
subsequent proteomic analysis have allowed a map of EV embedding proteins to be devised
(Exocarta and Vesiclepedia)120–123. Most representative EV surface proteins include
tetraspanins (CD9, CD63, and CD81) and major histocompatibility complex II (MHC II),
which are present on both exosomes and larger EVs119.
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1.2.2

Cancer cell EVs and their potential roles

In addition to the documented role of EVs in anticoagulation106 and removal of unwanted
cellular materials, new roles of EVs from different cell types are being recognizied124. EVs
are released from different types of cancers as well and it is believed that these messengers
are involved in inter- and intra-cellular communication in tumours. EVs may transfer
oncogenes, regulate angiogenesis, modulate the immune system, and establish premetastatic niche. Similar to normal cell EVs, cancer-derived EVs are heterogenous in
biogenesis, size-spectrum and potential roles (Figure 2). In addition, the molecular
pathways involved in the release of cancer-derived large EVs are similar to those
discovered in normal cells. Cancer cells actively release large EVs upon the activation of
small GTP-binding proteins, ARF1 and 6. ARF1 and 6 phosphorylate MLC, inducing
actomyosin contraction and membrane blebbing112,125. Intracellular calcium can also
activate scramblase and calpain in cancer cells to induce cytoskeleton rearrangement, a loss
of plasma membrane asymmetry, and membrane blebbing. Cancer cell EV release is also
regulated by the ESCRT machinery.

17

Figure 2: The heterogeneity of cancer cell EVs and their potential roles126. Cancer
cells release exosomes, microparticles (microvesicles), and large oncosomes. Apoptotic
cancer cells also release apoptotic EVs (APOs or Apo-EVs) as an EV subset. Different
molecular pathways in cancer cell EV biogenesis cause the heterogeneity of cancer cell
EVs.
Figure is reproduced here for educational purpose only and not for any commercial use.
Figure is included in the Ph.D. dissertation with attribution126.

Cancer cell-derived EVs can travel to distant sites and interact with different cell types. A
recent study has shown that cancer-derived EVs transfer EGFR to induce tumourigenesis
in nearby recipient cells127. Al-Nedawi et al. also reported that EGFRvIII overexpressing
U373 human astrocytoma cells transfer EGFRvIII to recipient U373 cells through
microvesicles. These recipient U373 cells started to express EGFRvIII, increased the
expression of VEGF, and increased colony formation in soft agar127. Antonyak et al.
showed that microvesicles from MDA-MB 231 breast cancer cells and U87 glioblastoma
cells transform normal NIH-3T3 cells. MDA-MB-231 and U87 cell-derived microvesicles
contained tissue transglutaminase (tTG) linking to fibronectin allowed 3T3 cells to acquire
anchorage-independent growth in vitro and in vivo128. Studies also illustrate how cancer
cell-derived EVs can compromise the host immune system. Taylor et al. showed that
ovarian cancer patient serum-derived EVs are enriched in FasL. The exposure of Jurkat T
cells to ovarian cancer-EVs induced apoptosis, which was mediated by FasL129. Cancer-
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derived EVs have also been shown to cause CD8+ T cell apoptosis and proliferation of
CD4+CD25+FOXP3+ Treg cells130,131.
In addition to microvesicles and exosomes, cancer cells generate large ‘oncosomes’. Large
oncosomes appear to be unique to cancer cells and are typically 1-10 m in diameter.
Studies have shown that oncosomes are detected from amoeboid cell-enriched tumour
tissues and plasma samples of metastatic prostate cancer patients, but not from benign
tissues or plasma samples. Oncosomes are generated from non-apoptotic plasma
membrane blebbing and fission, processes similar to microparticles. Acquisition of an
amoeboid phenotype is facilitated by the overexpression of certain oncoproteins such as
myristoylated Akt1, heparin-binding epidermal growth factor, and caveolin-1. Cancer cells
may also lose cytoskeletal regulator Diaphanous-related formin-3 (DIAPH3) or activate
Akt1 and EGFR pathways to induce oncosome formation126,132. In comparison to normal
cell-derived large EVs, oncosomes show the presence of caveolin-1 and are enriched in
cytokeratin-18. Levels of tetraspanins (CD9, CD63, CD81), however, is low
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. Despite

these differences, oncosomes share select exosome- and large EV-specific proteins such as
ALIX and ARF6126,134.
As the name suggests, oncosomes carry materials that may be categorized as oncogenic.
Minciacchi et al. showed that oncosomes derived from prostate cancer cell lines or plasma
of metastatic prostate cancer patients contain active AKT1 (phosphorylated form) that
activates MYC in fibroblasts. The activation of MYC in fibroblasts increased the size of
DU145 xenografts and induced angiogenesis135. Another mechanism by which oncosomes
facilitate cancer progression is remodeling of extracellular matrices in metastatic niche136.
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1.2.3

Intravascular cancer cell death and its involvement in cancer
cell EV biogenesis

As mentioned earlier, intravasated cancer cells experience stressors while in the circulation.
Cancer cells are highly susceptible to different types of cell death including apoptosis,
anoikis, and necroptosis in the circulation137. These cell death pathways are also involved
in cancer cell EV release and will be discussed here.

1.2.3.1

Apoptosis

Apoptosis is a programmed cell death that removes old, damaged or unneeded cells.
Apoptosis triggered by multiple factors that include endogenous stimuli (ageing and
cellular damage) and exogenous stimuli (infection, inflammation, engagement of proapoptotic receptors)138. The hallmarks of apoptosis are plasma membrane blebbing,
caspase activation, nucleus condensation, and generation of apoptotic bodies which are
engulfed by macrophages, neutrophils, and dendritic cells139. Cystine-dependent aspartatedriven proteases (Caspases) are the main effector proteins in apoptosis138. Pro-apoptotic
signals cause cytochrome C release from mitochondria, forming complexes with apoptosis
activating factor-1 (Apaf-1)140. Caspase-9 joins the complexes to form apoptosome that
activates caspase-3, an executioner caspase. Activated caspase-3 cleaves the C-terminus of
Rho-associated coiled-coil containing protein kinase 1 (ROCK1) and induces
constitutively active myosin light chain kinase (MLCK) that phosphorylates the light chain
of myosin II. MLCK activates myosin II and following cortical actin contraction by sliding
myosin II, which increases intracellular hydrostatic pressure producing membrane blebs.
Maturing blebs clear the original actin lining and are released. Growing blebs contain
nuclear DNA fragments generated by caspase-activated DNAse (CAD) which is also
activated by caspase-3. Membrane blebs also pack other cellular organelles such as the
Golgi apparatus, endoplasmic reticulum, and mitochondria. During this packaging process,
apoptotic bodies or apoptotic EVs (Apo-EV) are released into the bloodstream141. Lastly,
lipid scramblases and phospholipases expose PS (“find-me” and “eat-me” signal),
attracting phagocytes. If apoptotic cells are not phagocytosed, uncleared apoptotic cells or
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apoptotic bodies/Apo-EVs can become unstable and undergo membrane rupture, causing
the release of intracellular materials through a process called secondary necrosis141.
Secondary necrosis can cause chronic inflammation and autoimmune disease.
Emerging studies show that Apo-EVs of cancer cells exhibit oncogenic effects rather than
simply dead cell debris which is engulfed by phagocytes. Apo-EVs can carry nuclear
proteins (histones) and organelles (mitochondria, endoplasmic reticulum, and ribosomes),
whereas other EV subsets typically carry proteins and genetic material. Hayakawa et al.
showed the presence of bioactive mitochondria in astrocyte-derived Apo-EVs142. They also
showed that transferring these EVs improved survival and differentiation of neurons in
infarcted regions142. Similarly, Pavlyukov et al. showed that apoptotic mouse glioblastoma
cells upregulated spliceosome protein RBM11 and EVs released from these apoptotic cells
transferred RBM11 to recipient glioblastoma cells143. The recipient cells exhibited
increased cyclin D1 and mouse double minute 4 (MDM4), proteins regulating cell cycling.
In addition, spliced isoforms of cyclin D1 (D1a) and MDM4 (4s), which are pro-oncogenic,
were found143. These studies show that cancer cell Apo-EVs may be involved in cancer
progression, and perhaps recurrence following initial treatment.

1.2.3.2

Anoikis

Detachment of cells from extracellular matrix or lack of required substratum may induce a
form of programmed cell death called anoikis (loss of “home” or “homelessness”)144.
Anoikis is also a defence mechanism which prevents reattachment of detached cells at
abnormal sites and dysplastic growth. Failure in anoikis can cause ectopic cell proliferation
and even lead to tumour formation. However, cancer cells can develop resistance to anoikis
by switching their integrins, undergoing EMT, constitutively activating pro-survival
signaling, and manipulating their metabolic processes.
Interaction of cells with extracellular matrix is primarily mediated through integrin
receptors

26,27,147,148,149

. Cancer cells exhibit differential integrin expression patterns

compared to normal counterparts, which allow the cells to grow and avoid cell death
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mechanisms. Human melanoma cells, for example, express 3 integrins which are not
expressed in benign nevi or normal melanocytes48,150. Invasive and androgen-resistant
prostate cancer cell lines also show 3 expression, whereas androgen-sensitive and noninvasive LNCaP cell lines do not151. Integrin 5 has also been shown to counter anokis,
although its level is quite low compared to other integrins152. Expression of pro-survival
integrins such as 6 integrin can induce resistance to anoikis and maintenance of an
invasive phenotype as well153. Overexpression of the 6 subunit induced cancer cell
migration and secretion of metalloproteinase-3 (MMP-3), and prolonged EMT in cancer
cells153.
Cancer cells undergoing EMT acquire an invasive phenotype and an anti-apoptotic and
pro-survival gene patterns154. Snail, ZEB1/2, Twist, nuclear factor-κB, and HIF1/2 are
common transcription factors associated with EMT155. Twist also increases Bcl-2144. Snail1 has been shown to inhibit Bid, caspase-6, and PTEN to evade anoikis144. Inhibition of
PTEN leads to the activation of PI3K/Akt pathway and the discharge of Bad156. HIF-1 can
activate Twist and Snail to maintain EMT and anoikis resistance in cells156. HIF-1 can also
increase EGF expression and activate the MAPK pathway, inducing degradation of proapoptotic proteins such as Bim and Bmf156.

1.2.3.3

Necroptosis

Over last two decades, “extrinsic” apoptotic cell death has been shown to switch to
programmed necrotic cell death. In contrast to homeostatic and anti-inflammatory
apoptosis, necroptosis causes inflammation. The best-characterized extrinsic necroptosis
pathway is mediated via the tumour necrosis factor receptor-1 (TNFR1) complex157.
Tumour necrosis factor-α (TNF-) extrinsically induces apoptosis by activating TNFR1
and the formation of TNFR1 signaling complex (TNF-RSC, complex 1). The complex 1
recruits receptor-interacting serine/threonine-protein kinase 1 (RIPK1), TNFR1-associated
Death Domain protein (TRADD), Fas-Associated Death Domain (FADD), TNFRassociated Factor 2/5 (TRAF2/TRAF5), and cellular Inhibitor of Apoptosis Protein
(cIAP1/2). If caspase-3 is inactivated or RIPK1 undergoes deubiquitination (for example,
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by cylindromatosis (CYLD)), TNFR1-driven signaling switches to necroptosis. In
addition, deficiency in cIAP1/2 in the presence of activated RIPK1, leads to recruitment of
RIPK3 to form an alternative protein complex called the complex IIb or necrosome.
Activated RIPK3 then recruits mixed lineage kinase domain-like protein (MLKL) to the
complex IIb and phosphorylates it. Activated MLKL proteins form an oligomer and
translocate from the cytosol to the plasma membrane. Plasma membrane-localized MLKL
oligomers create pores and cause a rapid influx of Ca2+ into the cell, which subsequently
leads to membrane lipid scrambling and PS exposure158. Such plasma membrane disruption
compromises membrane integrity and induces the release of cellular contents.
Although RIPK1-dependant necroptosis is considered the canonical pathway, toll-like
receptor (TLR) 3 and 4 also participate in necroptosis in response of innate immune system
to pathogens such as bacteria, virus, as well as several endogenous threats159. Signaling
through TLR3 and 4 enhances TNF- production and may also induce the formation of
lysosomal cathepsin D (CTSD) and mitochondrial antiviral signaling protein (MAVS)
complex that recruits RIPK1 and activates necroptosis159.
Although necroptosis is primarily viewed as a player in inflammatory diseases, emerging
studies show the involvement of necroptosis in neoplasia. Yatim et al. have shown that
RIPK3-RIPK1-dependant necroptosis in NIH-3T3 induces NF-B expression and
enhances dendritic cell maturation and antigen presentation to cytotoxic CD8+ T cells160.
This study suggests that necroptosis may be utilized against cancer cells to increase T cell
priming. Yang et al. have demonstrated that RIPK3 induces type 1 interferon (IFN)
response in necroptotic mouse colorectal and lung cancer cells161. These necroptotic cells
released ATP and high mobility group box-1 (HMGB1) that recruited CD11c+CD86+
dendritic cells and CD3+CD8+ cytotoxic T cells161.
Similar to apoptosis, necroptosis has been linked to EV release (Figure 3). Gong et al.
have shown that ESCRT-III complex participates in MLKL-induced plasma membrane
disruption162. In their study, ESCRT-III complex translocated to the sites of MLKLinduced plasma membrane holes and repaired membranes by shedding EVs. Yoon et al.
also showed that MLKL-induced necroptosis in human liver and colorectal cancer cells
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releases EVs163. Specifically, the researchers showed that MLKL-depleted HepG2
hepatoma cells had a reduction in ILVs within MVBs, whereas the size of MVBs increased.
Decreased number of ILVs resulted in a decrease in MLKL-induced EV release. MLKLdepleted

HT-29

colon

cancer

cells

also

exhibited

a

decrease

in

EVs163.

Immunoprecipitation of EVs from necroptotic HT-29 cells showed that MLKL proteins
interacted with ESCRT and flotillin 1 and 2 proteins. These results imply that MLKL
proteins interact with ESCRT to induce EV release during necroptosis. Lastly, a study
identified phosphorylated MLKL in EVs from necroptotic mouse bone marrow-derived
dendritic cells, possibly suggesting that extrusion of EVs with phosphorylated MLKL is an
adaptive mechanism to suppress cell death163. Together, these studies illustrate the
involvement of necroptosis in EV release that may participate in cancer progression.
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Figure 3: Participation of ESCRT-III complex in MLKL-induced necroptosis causes
cellular EV release162. (A) RIPK3-MLKL signal transduction during cell necroptosis can
induce the exposure of PS to the outer plasma membrane. ESCRT-III complex can
intervene in the plasma membrane repair process. During this process, necroptotic cell can
shed parts of damaged plasma membrane as EVs to resuscitate or cells undergo membrane
rupture if they have overwhelming plasma membrane damages. (B) ESCRT-III complex is
recruited to the site of MLKL-induced plasma membrane damage and induces EV
biogenesis and release to repair the damage.
Figure is reproduced here for educational purpose only and not for any commercial use.
Figure is included in the Ph.D. dissertation with attribution162.
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1.2.4

Current methods of cancer cell EV isolation and detection

EV studies require precise methods of identification, quantification and purification. The
nature of biofluids from which EVs are harvested also poses challenges. Investigating
protein compositions of EVs is also confronted with contaminants such as soluble proteins
and platelets. Fortunately, there are a few established techniques of EV detection,
purification and quantification to adopt for different biofluids.

1.2.4.1

Microscopy-based EV imaging

Imaging of cancer cell-derived EVs can be performed both in vitro and in vivo. In vitro EV
imaging can identify the presence of surface antigens as biomarkers. In vivo imaging can
contribute to the understanding of molecular and biological mechanisms of EV biogenesis
and release. Transmission electron microscopy (TEM) and scanning electron microscopy
(SEM) can reconstruct a clean image and topography of EVs in a broad size spectrum by
using electron beams164. Atomic force microscopy (AFM) also creates a topographic image
of EV by using a probe made by silicon or silicon nitride. AFM can image most EVs with
a resolution limit close to 1 nm164.
Fluorescent fusion proteins allow real-time visualization of EV release from cancer cells.
Wallace et al. tagged a palmitoylation signal with enhanced GFP (EGFP) and tdTomato
red fluorescent proteins to label the inner plasma membrane of glioblastoma cells and 293T
cells165. Confocal microscopy-based live cell imaging revealed that GBM and 293T cells
exchanged EVs. Mittelbrunn et al. introduced GFP-tagged CD63 in Raji B and J77 T cells
and collected EVs. These EVs were then introduced to unmodified Raji B and J77 T cells.
They observed uptakes of GFP-tagged CD63 in the recipient cells166. In addition to labeling
proteins, fluorescent dyes such as DiD (DiIC18(5); 1,1`-dioctadecyl-3,3,3`,3`tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate) and PKH dyes (PKH67 and
PKH26) may also be utilized to track EVs. Grange et al. labeled mesenchymal stem cells
(MSCs) and MSC-derived EVs with DiD167. PKH67 and PKH26 dyes are also lipophilic
and bind to the lipid bilayer of the plasma membrane of cells168,169. Carboxyfluorescein
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diacetate succinimidyl ester (CFDA), commonly used to measure proliferation, can also
label both cancer cells and EVs derived from the labeled cells170.

1.2.4.2

Nanoscale flow cytometry

Nanoscale flow cytometry (nFC) in studying cancer cell EV quantification has emerged as
a preferred technique. It allows the analysis of individual EVs and the detection of multiple
surface antigens by using fluorophore-tagged antibodies. nFC utilizes enhanced optics
comprising of large angle light scatter (LALS) and small angle light scatter (SALS), and
highly sensitive photomultiplier tube (PMT) (Figure 4)171 to determine EV size (between
100 nm and 1000 nm)171–174. The combination of multi-channeled laser and two-way light
scattering strategy can allow researchers to analyze the presence of several surface antigens
in different EV subsets. Gomes et al. have standardized nFC detection and quantification
of EVs in the laboratory and clinic172. They showed that nFC provides an accurate detection
of platelet-derived microparticles in various human plasma samples. They also showed that
nFC provided a consistent CD41-positive microparticle quantification between light
scattering-only detection and fluorescence-only detection (Figure 4)172.
The biggest advantage of nFC is that it can quantify specific EVs in a high-throughput
manner. Biggs et al. showed that nFC detected different amounts of prostate-specific
microparticles among healthy volunteer plasma samples and samples from prostate cancer
patients with different metastatic stages. They detected microparticles with light scattering
detection and prostate-specific membrane antigen (PSMA)-tagged antibody. They
confirmed their results by detecting and quantifying microparticles in the culture media of
PSMA-positive human prostate cancer cell lines PC-3 and LnCAP171. Despite restricted
size detection (100-1000 nm), nFC technique is highly recommended to detect and quantify
cancer-specific EVs from both cell culture and patient plasma samples.
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Figure 4: Nanoscale flow cytometry detects cancer EVs by using calibration sized
beads172,173. (A) nFC uses light scattering and fluorescence to detect EVs with cancer
specific antigens between 100 nm and 1000 nm. (B) Light scatter (large angle light scatter
and small angle light scatter) based nFC calibration with non-fluorescent silica beads of
different sizes. (C) Fluorescent latex and non-fluorescent silica beads based nFC
calibration. (D) Histogram displays individual counts of each size-calibration bead.
Figures (top and lower panel) are reproduced here for educational purpose only and not
for any commercial use.
Figures are included in the Ph.D. dissertation with attribution172,173.

1.2.4.3

Ultracentrifugation

Centrifugation-based EV isolation techniques for a small EV collection from conditioned
medium have been well-established. Kowal et al. showed that high centrifugal forces (
100,000 xg) could afford a preparation of small EV pellets119. Studies utilizing this
technique remove cell debris and EVs larger than 220 nm to isolate small EVs. Cell culture
conditioned media and various biofluids (for example, blood, urine, cerebrospinal fluid)
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can be spun with low centrifugal force (300 xg) to remove cell debris and apoptotic bodies,
followed by higher centrifugal force (2,000 xg) to remove additional cell debris and dead
cells. Once dead cells and debris are removed, high speed spins from 10,000 xg up to
50,000 xg can precipitate large EVs (microparticles and oncosomes)125,175. A final spin
with high speed over 100,000 xg can precipitate both large and small EVs. Collected EVs
can be stored in phosphate buffered saline (PBS) at -80C and used for EV protein
characterization and biomarker discovery with the aid of mass spectrometry, western blot,
and immunoprecipitation176.

1.2.4.4

Ultrafiltration

Ultracentrifugation is highly versatile in separating different EV subsets and the quality of
EV subset separation is also reliable. However, ultracentrifugation requires specialized
equipment capable of spinning samples at 200,000 xg. In addition, ultracentrifugationspecific tubes are needed, which are expensive. Instead of expensive equipment,
polyethersulfone nanomembrane filter with 100 kDa molecular mass cut-off can be used
to collect EVs by concentrating samples177. In addition, any bench-top centrifuge can spin
ultrafiltration tubes to collect EVs. Ultrafiltration is also faster and simpler to isolate EVs,
and easily paired with nFC to quantify EVs. Miranda et al. showed that ultrafiltration can
provide

similar

urinary

EV

concentration

with

the

one

collected

from

ultracentrifugation178. Therefore, ultrafiltration is an economical and time-saving EV
isolation technique for high-throughput EV quantification.

1.3 Motivation and hypothesis
1.3.1

Motivation

Although there is an urgent need to combat cancer metastasis, targeting the multiple steps
in the metastatic cascade has been limited. My work centers around the notion that cancer
cell extravasation must be inhibited to effectively prevent metastasis. Cell extravasation
involves changes of cancer cell phenotype to an invasive one, which is critical to
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metastasis. Extravasation is also the last key step before cancer cells home to a secondary
site. If we are able to alter the efficiency of cancer cell extravasation to secondary sites, we
may be able to contain cancer spread. However, to understand the cellular and molecular
changes that play a role in extravasation, an in vivo system that allows these mechanisms
of extravasation to be examined in real-time is needed. Towards this goal, I focused on the
economical CAM of chicken embryo to view and quantify cancer cell extravasation
(Chapter 3). Observations made in this CAM assay using prostate cancer cells led to the
discovery of cell volume changes as perhaps necessary events in extravasation. These cell
volume changes were associated with the release of extracellular vesicles (EV).
Extravasation and EV release were also associated with induction of cell death pathways
(Chapter 4). Together, my studies developed an in vivo model of extravasation and
highlighted an important role of cell death pathways in extravasation.

1.3.2

Hypothesis

Modelling cancer cell extravasation using the chorioallantoic membrane platform will
allow real-time monitoring of the cellular events required in the process and discovery of
novel underling mechanisms.

1.3.3

Research Objectives of the Study

There are three main objectives:
1. To optimize in vivo quantification of cancer cell extravasation using the CAM of
chicken embryos and the reproducibility of the model (Chapter 2).
2. To elucidate the relationships between cancer cell volume changes and metastatic
efficiency, and extracellular vesicle release and cell volume change (Chapter 3).
3. To determine whether cell death pathways are involved in cell volume change and
extracellular vesicle release (Chapter 3)
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Chapter 2

2

Quantification of Cancer Cell Extravasation In Vivo

Contents of this chapter are published in Nature Protocols. Kim Y, Williams KC, Gavin
CT, Jardine E, Chambers AF, Leong HS. Nat Protoc. 2016; 11(5):937-48. Only
formatting changes were made to include the published work in this thesis.

2.1 Introduction
Metastasis is the process by which a primary tumour releases tumour cells into the
hematogenous or lymphatic system, resulting in the downstream colonization of distant
sites such as the brain, liver, lung and bone marrow1. There are four main steps in the
metastatic cascade: intravasation2–4; transit in the blood or lymphatic system5–7;
extravasation8,9; and adaptation to the secondary site10–13. Intravasation is the entry of
tumour cells into the circulation at the primary tumour site, and it is thought to require
migration past the endothelial cells of vessels distributed throughout the tumour. When
tumour cells enter the circulation, they are carried away from the site of intravasation and
arrest in the capillary beds of distant sites such as the liver, brain, bone marrow and lung.
After intravascular arrest at these distant sites, tumour cells may undergo extravasation,
which is the movement of cancer cells from the vessel lumen into the underlying tissue.
Studies using the CAM of chicken embryos and mouse lungs have shown that the vast
majority of metastases are found in the extravascular space and are rarely present in the
intravascular space (vessel lumen), suggesting that cancer cell extravasation is a key step
in the metastatic cascade9,14. Extravasation occurs at all distant sites, with varying
efficiencies15, and only a small percentage of extravasated tumour cells will successfully
adapt to the local microenvironment and proliferate to form a metastatic colony15–17.
In this protocol, we describe a technique to evaluate cancer cell invasiveness by quantifying
in vivo rates of cancer cell extravasation in the CAM of chicken embryos. Our laboratory
and others have used this protocol in recent research investigating the efficacy of target
genes9,18–20 or drugs9,20–22 in inhibiting or promoting cancer cell extravasation.
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This assay can also be used to study metastatic inefficiency (whereby only a small number
of tumour cells form metastases16), which can occur at various steps of the metastatic
cascade, including intravasation23, extravasation15 and adaptation to the new local
microenvironment24. Highly aggressive cancer cells, such as B16F10, tend to form large
numbers of metastases (particularly in the lung and liver), whereas less aggressive variants,
such as B16F1, form considerably fewer metastases25. Clones of tumour cells with invasive
phenotypes are able to persist because of their ability to overcome local restrictions (for
example, nutrient deprivation and hypoxia)26,27. Many metastatic cancer cells form
membrane protrusions known as invadopodia that mediate cancer cell extravasation and,
when blocked by depletion of invadopodia-specific factor Tks4/5 (tyrosine kinase substrate
with four/five Src homology 3 domains), have considerably reduced metastatic colony
formation9,28. However, various other cancer cell lines are also able to extravasate with
varying efficiencies with little to no invadopodia formation capacity, as determined by
gelatin-degradation assays29, suggesting that proteases might not always be integral for
transendothelial migration.

2.1.1

Comparison with other methods

Cancer cell extravasation has been studied using the in vitro Transwell assay, in which
cancer cells are seeded onto a Transwell filter pore system and allowed to translocate across
a well containing chemotaxis factors such as fetal bovine serum (FBS)30,31. This assay has
been used extensively to evaluate the effects of various genetic factors and pharmacologic
compounds on cancer cell invasion in a system analogous to the process of cancer cell
extravasation (Figure 5a). As a result of the Transwell assay, many molecular mechanisms
and cellular components have been implicated in cancer cell extravasation, such as various
Rho GTPase effectors18,32,33, chemokines34,35, integrins8,36,37, proteases38,39 and cytoskeletal
proteins40–42. However, there are three major caveats with in vitro–based assays. First,
translocation of cell volume in Transwell assays occurs through 2D circular pores ranging
from 3 to 12 µm in diameter, whereas extravasation probably occurs along endothelial
junctions belonging to an architecturally complex 3D microvasculature network43,44.
Second, in vitro assays are hemodynamically static, whereas both plasma proteins and
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circulating blood cells are key to promoting and counteracting biophysical forces acting
upon tumour cells as they attempt to extravasate. Most of the in vitro assays use cell culture
media supplemented with 10–15% FBS and not 100% uncoagulated plasma, so in vitro
experiments are missing the full range of plasma proteins and their rheological impact on
microcirculation. Recent publications have highlighted the use of endothelial cells to form
cell monolayers to simulate transendothelial migration45–47, but these systems lack the full
range of platelets, red blood cells and leukocytes needed to recreate in vivo hemodynamics.
Moreover, these microfluidic chips are not readily commercially available and require
trypsinization to remove cells (which may also remove the gelatin coatings needed for new
cell layers to form)48. Furthermore, they require continuous perfusion throughout the chip
and continuous monitoring (no monitoring is required after cancer cell injections in the
CAM). Third, most cells will eventually translocate across the Transwell over a 24- to 48h period of incubation in vitro, highlighting the permissive-ness of the Transwell filter. In
fact, given that very few cells die in vitro if they fail to translocate (whereas large numbers
would die in vivo), the Transwell assay uses an arbitrary time frame to compare treatments
or cell genotypes. Given the technical limitations of in vitro–based invasion assays, in vivo
cancer cell extravasation studies are rapidly gaining popularity.
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Figure 5: Comparison of transwell invasion assay with the chorioallantoic membrane
(CAM) to quantify cancer cell extravasation and imaging intravascular and
extravascular cancer cells in the CAM. (a) Schematic of in vitro transwell invasion assay
in which cancer cells of interest are plated into the upper chamber of the Transwell system
and migrate across a pore membrane system to gain access to the lower chamber filled with
a chemotactic agent. (b) Schematic of in vivo cancer cell extravasation assay in which
cancer cells are injected intravenously (i.v.) and arrest within the capillary bed of the CAM.
Over time, a fraction of cells will successfully undergo transendothelial migration into the
stroma of the CAM. (c) Intravital image using confocal resonance scanning microscopy of
a cultured human prostate PC-3M-LN4 cancer cell in the intravascular space of the CAM.
When various other labeling agents are injected, such as Hoechst 33456 to stain nuclei
(blue), lectin-DyLight 649 to label the endothelial walls (purple) and Dextran-Alexa 555
to reveal the vessel lumen space (red), cancer cells such as PC-3M-LN4 (green) can be
properly visualized in the CAM capillary bed to determine whether the cells are
intravascular or extravascular. Scale bars, 10 m.

Although murine preclinical models remain the gold standard for simulating the metastatic
process in vivo, it can be difficult to study cancer cell extravasation rates in commonly
colonized mouse organs such as the lung and liver, as capillary beds are not accessible for
imaging. In contrast, the CAM of chicken embryos is well-suited for evaluating cancer cell
extravasation rates because it offers a flat, extensive capillary bed for imaging key steps of
the metastatic cascade, in some ways resembling a ‘2D lung’4,9,43,49–52. When labeling
agents such as fluorescently-conjugated lectins (Lens culinaris agglutinin), which label the
luminal surface of endothelial cells, or dextrans, which label the vessel lumen, are injected
intravenously (i.v.) into the CAM, the capillary bed becomes evident and appears as a thin
sheet in the middle of the CAM, with the stroma space immediately below it (Figure 5b).
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When cancer cells are injected into CAM veins, the cells will be present immediately
within this capillary bed and, over time, extravasate into the underlying stroma, which is
not labeled by the lectin, providing a clear distinction between intravascular and
extravasated cancer cells.

2.1.2

Advantages and limitations

This in vivo assay enables the investigator to evaluate the effects of a target gene or drug
at a specific step of the metastatic cascade, cancer cell extravasation. This preclinical
model can be used to determine the number of cancer cells that initially arrest in the
embryonic lung and the proportion of cancer cells that extravasate in the region of interest
(ROI) within 24 h. The key strength of this model is that cancer cells immediately arrest
within the capillary bed of the CAM, which is a 2D microvasculature network that spans
above and across the entire embryo when ex ovo. When cancer cells extravasate, the
majority will translocate into the stroma layer immediately below the CAM’s capillary bed
(Figure 5b). In some instances, the cancer cells will displace stromal cells, which appear
as circular voids throughout the CAM’s capillary bed (Figure 5c). When fluorescently
labeled lectins are injected into CAM veins, the identification of cells as intravascular or
extravasated becomes straightforward and rapid (Figure 5c). L. culinaris agglutinin lectins
are powerful reagents because of their high affinity for the glycocalyx of chicken embryo
endothelial cells, and they are relatively inexpensive, as only ~5 µg of lectins is needed for
each embryo. This enables the user to determine extravasation efficiency in a binary
manner and to generate quantitative data proficiently and in a high-powered manner. This
technique is also an excellent means of performing drug screens for compounds that inhibit
invasion or cancer cell extravasation in an in vivo environment. To begin these drug
screens, pretreatment of the cells before injection or co-injection of drugs can be performed
to determine the drugs’ effect on cancer cell extravasation. Subsequent drug administration
after the initial injection of cells is not necessary because cancer cell extravasation occurs
primarily within the first 12 h after the injection of cells, and drug bioavailability in vivo
is not normally an issue during that time frame. Moreover, given the small blood volume
of avian embryos (1.3–3.4 mL total), the use of biologics such as inhibitory antibodies or
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peptides is economically feasible with this model, as opposed to performing the same
experiments in mice, where more complex pharmacodynamic consideration is required.
This technique is also economically and scientifically scalable, as several different
treatments can be performed in the same day, using at least N > 6 for each treatment group
or genotype. The ability to generate experiments within 24 h that can evaluate various
groups or genotypes offers a high-throughput means of attaining in vivo results that are
meaningful to cancer cell metastasis without reliance on a rodent model. Although
performing end-point assays in immunocompromised mice will continue to be the gold
standard for oncology preclinical models, the opportunity to evaluate several groups or
treatments in this intermediate model is valuable, especially because mouse models are
more expensive and time-consuming to use.

Because of the low cost of each chick embryo ($0.50–1.00 per embryo), CAM assays for
each cell group or treatment group can be sufficiently powered (N > 15 embryos per group)
to readily achieve statistical significance between groups. Moreover, because of the highly
accessible nature of the CAM, cancer cells within the capillary bed or stroma can be readily
visualized using either wide-field or confocal fluorescence microscopy, without any hair,
adipocytes or skin obscuring the visualization of fluorescently labeled cells. The CAM
assay is also rapid; the injection of fluorescently labeled lectins that label the luminal
surface of endothelial cells allows the researcher to quickly and easily distinguish
intravascular cancer cells from extravasated cancer cells within just 24 h53.

A limitation of this assay is that only fluorescently labeled cells can be used, either by
expression of fluorescent proteins or by pretreatment with lipophilic fluorescent dyes such
as CellTracker (Thermo Fisher) dyes. In addition, although this model has been used to
understand many steps of angiogenesis and cancer metastasis in mammals, another
limitation may arise from the fact that mammalian tumour cells are operating in an avian
xenograft microenvironment. If the cancer cells require specific endocrinological factors
for viability, then this should be considered when performing extravasation assays in
embryos. Furthermore, it is essential that the investigator become skilled at the i.v.
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injection of cancer cells, and it is our aim with this work to provide a complete step-bystep guide to help researchers successfully reproduce this protocol.

2.1.3

Overview of the technique

There are four key stages to this method: preparation of ex ovo embryos, preparation of
cancer cells for i.v. injection into the CAM of chick embryos, intravital imaging of cancer
cells before and after extravasation, and wide-field imaging–based quantification of cancer
cell extravasation.

2.1.4

Experimental design

Eggs. There are many breeds and sizes of chicken embryos, but White Leghorn chicken
eggs are commonly used for scientific endeavors. A typical extravasation experiment
requires n > 10 embryos per group. A group can be defined as those embryos that receive
an injection of cancer cells that receive an overnight pretreatment of drug/therapy.
Cell lines. Adherent cell lines or those grown in suspension can be used for these
experiments. In this protocol, we present images and data obtained with the PC-3M-LN4
prostate cancer cell line. Many different cancer cell lines have been used and injected into
the CAM of chick embryos, and the proportion that successfully extravasates in vivo is
correlated to metastatic efficiency. Ideal positive and negative control cell lines will be offtarget control knock-down cells and cells treated with vehicle control (negative control).
Injection techniques. It is essential that the bore width of the microinjector needle have
the same diameter as the vein for the injection of cancer cells, as this will minimize blood
loss and maximize embryo viability after the injection.
Incubation conditions. Before the fertilized eggs are cracked, incubation of the eggs is
necessary at 22 °C in any incubator for up to 3 h before cracking. Chicken embryo
incubation units at 39 °C are used for incubation of chicken embryos after cracking and
microinjection, and no CO2 is used. Cancer cell culture conditions are at 37 °C.
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Counting techniques. The means of determining extravasation efficiency is the
enumeration of cancer cells at T = 0 and at T = 24 h that are within a 1-inch x 1-inch
aluminum foil window as pre- pared by the investigator. Confocal microscopy is used to
confirm cancer cell extravasation at T = 0 and T = 24 h after injection.
Extravasation efficiency. To determine whether cell lines are suitable for extravasation
efficiency analysis, the investigator must check that all the cells are extravasated 24 h after
injection. Confocal microscopy must be performed on a subset of chick embryos (N > 4)
to determine the percentage of cells present within the foil window that are intravascular
or extravascular. This assay can be readily adapted to study metastatic colony formation
by the addition of a 7-d incubation of the embryos after extravasation efficiency analysis
(T = 24 h). Cancer cell extravasation rates and metastatic colony formation rates can be
studied sequentially in a rapid and straightforward manner. When you are performing an
extravasation efficiency experiment, always rely on N > 4 for each treatment/cohort/cell
type. Thus, in the event that 1–2 animals die after the T = 0 injection of cancer cells, there
will at least be N = 3 per group for analysis.
Time course. It is important to be aware that although a typical extravasation experiment
takes 24 h to elapse, considerable preparation is required to have the proper number of
embryos ready for the number of groups being tested. For this reason, not all groups are
evaluated at the same time, and experiments are often split up and performed on different
days or weeks.

2.1.5

Reagents

Fertilized white Leghorn eggs. Our experiments were conducted in accordance with
guidelines of the Institutional Animal Care and Use Committee at Western University.
Consult with your institute’s Animal Care and Use Committee to determine whether
chicken embryos are considered animals or embryos. At most research institutions, chicken
embryos that are maintained from embryonic day 8 to day 22 are not considered animals if
the embryos are terminated at day 22. As these experiments require ex ovo embryos, the
absence of the egg shell will result in the gradual termination of the embryo because of the
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lack of calcium needed for embryonic bone development. Cancer cell line of interest used
in your research should be regularly checked to ensure that they are authentic and that they
are not infected with mycoplasma. Lectin-FITC/lectin-rhodamine/lectin-DyLight 649, L.
culinaris agglutinin LCA (Vector Laboratories, cat. no. FL-1041/FL-1042, always freshly
prepare this compound from the stock vial on the day of use).

• dH2O
• Dulbecco’s
• FBS
• Cell

PBS (D-PBS, pH 7.2−7.4; Wisent, cat. no. 311-010-CL)

(heat inactivated; Wisent, cat. no. 080-910)
culture medium (unsupplemented) specific to the cell line for

experimentation
• Trypsin,
• 70%

0.05% (wt/vol) and EDTA 0.53 mM (Wisent, cat. no. 325-042-CL)

ethanol (in dH2O)

• CellTracker

green CMFDA (5-chloromethylfluorescein diacetate) dye (Life

Technologies, cat. no. C2925)

2.1.6

Equipment

• Digital

sportsman egg incubator (GCQ, cat. no. 1502)

• Digital

hatcher egg incubator (GCQ, cat. no. 1550)

• Rubbermaid

plastic container (Guillevin, cat. no. RH3-228-00-BLU) with 1-cm-

diameter holes drilled into sides, spaced 5 cm apart around the side perimeter of each
container
• Polystyrene

weigh boats for holding ex ovo chicken embryos (VWR, cat. no.

12577-01)
• Square

Petri dishes as lids for weigh boats containing ex ovo chicken embryos

(Simport, VWR, cat. no. 25378-115)
• Dremel

drill tool

• Dremel

cutoff wheel bit no. 36 (Dremel, cat. no. 409)

• Tygon

R-3603 laboratory tubing, 50 ft (1/32-inch inner diameter, 3/32-inch outer

diameter, 1/32-inch wall thickness; VWR, cat. no. 63009-983)
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• Syringes

for injections (1-mL maximum volume capacity, box of 100; BD

Biosciences, cat. no. 309602)
• Hypodermic

needles of injections (18-gauge needles, box of 100; BD

Biosciences, cat. no. 305195)
• Intellitemp

heat mat (19.7-inch x 11.8-inch, 30 W, Big Apple Herpetologicals)

• Vertical

pipette puller (David Kopf Instruments, Model 720)

• Sodium

borosillicate capillary tubes (o.d., 1.0 mm; i.d., 0.58 mm; 10 cm length; Sutter

Instrument, cat. no. BF100-58-10)
• Circular
• Fine

glass coverslips, no. 1 (18 mm; VWR, cat. no. 16004-300)

forceps (VWR, cat. no. 25607-856)

• Scissors
• Vacuum
• Avian

grease (VWR, cat. no. 59344-055)

embryo imaging unit (custom made)

• Aluminum
• Pyrex

foil

Petri dish (100 x 20 mm; VWR, cat. no. 89000-306)

• Dissecting
• Wide-field

scope
fluorescence upright microscope fitted with 4x and 10x long-

distance objectives
• Refrigerated
• Kimwipes,
• Cell

Benchtop Centrifuge (Eppendorf)

13 x 21 cm, Box/280 (VWR, cat. no. 470173-504)

culture supplies (cell culture flasks, Falcon tubes, P1000 micropipette,

pipette gun and so on)

2.1.7

Reagent set up

Cells
Perform cell culture with various adherent or suspension cancer cell lines as required. To
assess the effect of a drug on cancer cell extravasation, ensure that each treatment is
performed in a T75 cell culture flask. Each flask should contain cancer cells that are grown
to a confluency of ~80–90%. Depending on the injection effectiveness by the investigator,
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a single T75 flask may provide enough diluted cells for injection into 6–18 embryos.
Although suspension cancer cell lines can be used in this experiment, the following
procedure provides instructions for adherent cell lines only.

CellTracker dye
To prepare the dye for cell labeling, add 1 mL of DMSO to a 1.5-mL Eppendorf tube, mix
it vigorously and leave it in the dark at −20 °C until needed for Step 17 (up to a maximum
of 1 month).

2.1.8

Equipment set up

Microinjection needles Prepare needles drawn from borosilicate glass capillary tubes
using a pipette puller (Kopf Instrumentation). Prepare needles that are as long and slowly
tapered as possible by adjusting the heat and solenoid settings on the puller. Settings on the
720 Kopf model are generally 16.3 (heater) and 2.3 (solenoid). Needles should be prepared
before cell injection, sprayed with 70% ethanol and then stored in a sterile dish with a lid
for at most a week. If needles are to be reused, simply spray the needles with 70% ethanol
again.
Aluminum foil regions of interest Fold the aluminum foil in half and cut out a window
that has an internal width of 1 inch with scissors. The frame of this aluminum foil window
should be less than 1/4 inches in width, and the window should be square-shaped. Unfold
all foil windows and place them in the Pyrex Petri dish and autoclave before use. The
window should have an internal open square dimension of at least 1 inch x 1 inch. For
wide-field fluorescence microscopy, we use an Olympus upright microscope that has a
Mercury Arc lamp light source and a full set of dichroic filters for visualizing GFP- and
RFP-based fluorescence signal. No digital camera is needed for this microscope. For
confocal fluorescence microscopy, we use a Nikon Fast A1R confocal upright microscope
fitted with several oil-immersion objectives (20x and 60x objectives) and laser lines (405,
488, 561 and 643 nm).
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2.2 Protocols
2.2.1

Preparation of ex ovo chicken embryos

Timing 9 days
1. When fertilized eggs arrive at the laboratory, place the eggs in the hatcher and incubate
them for 4 d at 39 °C at a relative humidity of >70% with rotation as per the instructions
for the hatcher.
2. Ideally, eggs are incubated at 39 °C in the hatcher on the day of receipt; however, if this
is not possible, place the eggs at 4 °C for up to 3 d for scheduling purposes. Move the eggs
from 4 °C to the 22 °C incubator for 3 h before finally placing them in the hatcher incubator
at 39 °C for 4 d at a relative humidity of >70% with rotation as per the instructions for the
hatcher.
Critical step: Do not wait more than 4 days after fertilization of the eggs to begin step 2.
3. On the day of egg cracking, prepare a Dremel tool (Figure 6a) by fitting with a cutting
disc (no. 36 cutoff, 15/16-inch diameter, included in the tool set) that is attached to a rod
platform and fixed at a user-defined level using a three-finger clamp.
4. Spray down the entire Dremel tool and cutting disc with 70% ethanol.
Critical step: As the cracking step is a major source of contamination of embryos, the
cutting disc must be properly sprayed down with 70% ethanol.
5. Place the egg on its side for 10 sec so that the embryo and yolk move to the center of the

egg. To crack open the egg shell, hold both ends of the egg with both hands and lightly roll
or coat the middle ‘waist’ of the egg shell with 70% ethanol in a weigh boat.
6. With the Dremel tool operating at medium speed, make four shallow cuts around the
middle ‘waist’ of the egg (Figure 6b).
Critical step: Cuts should be equally spaced from one another so that the cracking step
(Step 7) is clean and quick.
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Figure 6: Preparation of ex ovo chicken embryos and microinjector assembly for i.v.
injection of cancer cells or labeling agents. (a) Egg-cracking station consists of a plastic
shield and a Dremel cutting tool (left image). Eggs are laid on their side before cracking.
(b) With the Dremel cutting tool, 2–3 cuts are made along the middle of the egg, and then
the egg is gently split open, and the embryo and its yolk are placed into a weigh boat. (c)
Ex ovo chicken embryos are individually stored in disposable weigh boats and lids. (d)
Embryos are stacked and transported in batches using clamshell boxes. (e) Hundreds of
embryos are stored in large incubators for experimentation. (f) Unassembled and
assembled microinjectors, which are used to i.v. deliver cells and/or labeling agents via
small vessels present in the CAM for the extravasation efficiency assay. (g) The pulled
microneedles are modified such that the tip is broken so that a bore size (bottom needle) of
sufficient size can be used to inject cancer cells and to prevent clogs.

7. Spray a new weigh boat with 70% ethanol. Once the ethanol has dried, lay the egg on
the weigh boat on its side and gently roll it back and forth while placing downward pressure
on the middle of the egg. The egg shell will gently crack open, and when it is fully split
quickly pull the two egg shell halves apart and lay the yolk and its attached embryo in the
base of the weigh boat. The fertilization rate will vary depending on the hatchery. Discard
unfertilized eggs and reuse weigh boats for other fertilized eggs.
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Critical step: To determine whether the embryo is viable, look for a coin shaped red
structure on top of the yellow yolk. A beating heart should be observed, which indicates
the embryo is alive. Ensure that the yolk is not pierced and that it remains intact
immediately after eff shell cutting and splitting. If the yolk is broken open and leaks into
the albumin, the chances of mortality considerably increase.
8. Place a transparent square plastic Petri dish cover over the weigh boat that contains the
ex ovo embryo (Figure 6c). Repeat Steps 5–8 for additional eggs as required by the
experiment.
Critical step: Although it is possible to reuse weight boats and the transparent lids, they
must be washed and sterilized by being sprayed down with 70% ethanol. Omitting this
sterilization step increases the risk of contamination.
Pause point: It is best to crack 8-10 eggs at a time before pausing between cuts. Pauses can
last anywhere between 10s and 5min.
9. Place fully enclosed embryos into larger plastic containers for transport and storage.
Critical step: The Rubbbermaid plastic containers must be laid out with six of the
transparent square lids and then filled with 200 mL of dH2O. Each container can hold 18
embryos in stacks of three (Figure 6d)
10. Place the containers with embryos into an egg incubator (Figure 6e) set at 39 °C with
>70% relative humidity with no rocking. If eggs are cracked 4 d after fertilization, incubate
the embryos for another 5 d until they are at embryonic day 9.
Critical step: The base of each container (with a maximum of 18 embryos) must be refilled
every day with enough water to cover the bottom of the container. Do not overfill with
water, because during shifting of embryos water can enter the inner chamber of the weigh
boats and kill the embryos (Table 2).
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2.2.2

Preparation of cancer cells for injection

Timing 1–3 h
Critical 1: For optimal counting, perform Steps 11-22 in the morning so that counting can
be performed in the early afternoon.
Critical 2: Do not perform experiments with cells grown to full confluency, as they may
not extravasate at the same rate as cancer cell lines grown to ~80-90% confluency.
11. Take the T75 flask containing cells grown to ~80–90% confluency and discard the
medium into a flask containing 20% bleach, and quickly fill the flask with enough
Dulbecco’s PBS (D-PBS) to cover the flask surface. Discard D-PBS into the flask
containing 20% bleach and repeat this washing step twice.
Critical step: Do not use pipettes or aspiration to remove the medium, because the cells
will be exposed to air in the short amount of time needed to aspirate D-PBS. Instead,
quickly discard the used medium and quickly fill the flask with D-PBS to wash off any
leftover medium. If cells are exposed to air during the wash steps, it will noticeably affect
cell viability upon i.v. injection.
12. At the last wash step, discard D-PBS and immediately add 2 mL of 0.05% Trypsin with
0.053 mM EDTA. Ensure even distribution of Trypsin + EDTA (or EDTA for controls)
across the entire flask surface that has the cancer cell monolayer. Incubate this flask at 37
°C for 5–8 min. Using an inverted light microscope, ensure that all the cells have ‘lifted’
off before proceeding.
Critical step: Cell culture techniques for the preparation of cells for injection are cell-linespecific. If the goal is to avoid using Trypsin to harvest cells for use in the extravasation
assay, then use EDTA to prepare cells and use 2 mL of 5 mM EDTA in PBS and let it sit
for 2 min. Remove EDTA and tap the plate/flask to dislodge cells.
Critical step: Do not leave the cells in Trypsin for more than 15 min; otherwise, receptors
and proteins on the cell membrane will be cleaved, making comparisons between groups
uncontrolled.
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13. Add 7 mL of D-PBS to the flask, collect all cells and transfer them to a sterile 15-mL
Falcon tube. Add another 5 mL of D-PBS to the flask to collect all residual cells and add
to the 15-mL Falcon tube.
14. Centrifuge the cells at 200 xg for 10 min at room temperature (25 °C). After
centrifugation, carefully remove the supernatant and discard it. Add 10 mL of D-PBS and
resuspend using a 10-mL-capacity pipette. Centrifuge the cells at 200 xg for 10 min at room
temperature. (Table 2).
15. After centrifugation, carefully remove the supernatant and discard it. Using a P1000
micropipette, add 1 mL of D-PBS to the cell pellet and resuspend the cells very slowly and
gently. The cell pellet will break up into smaller portions, and when drawn into the pipette
tip these pieces may become lodged against the side of the pipette tip. To prevent this,
gently disturb the cell pellet by shooting the D-PBS into the cell pellet so that smaller
fragments are released into the D-PBS.
16.Transfer this cell suspension into a 1.5-mL Eppendorf microcentrifuge tube. With an
unused tip, add 0.5 mL of D-PBS to the 15-mL Falcon tube, and then retrieve all residual
cells and transfer them to the 1.5-mL tube containing the rest of the cells. Centrifuge this
tube at 200 xg for 10 min at room temperature. Remove the supernatant by aspiration and
gently resuspend the cell pellet in 1.0 mL of D-PBS.
17. If the cells are already fluorescently labeled, then proceed to Step 19. If not, you will
need to label the cells with CellTracker dye at this step. Add 2 L of diluted CellTracker
dye to the cell suspension and mix the entire cell suspension for 10 sec. Leave it on ice for
10 min in the dark. The CellTracker dye will remain bound to the cells for the next 24 h.
18. Centrifuge the cell suspension at 200 xg for 10 min at room temperature. Gently remove
the supernatant and resuspend the cell pellet in 1.0 mL of D-PBS. Repeat this wash step.
19. Use a hemocytometer or automated cell-counting machine to determine the
concentration of cells in 10 L of the washed cell suspension. Dilute the cells to 5.0 x 105
cells per mL with D-PBS.
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Critical step: If the cell concentration is >5.0 x 105 cells per mL, clogs may appear in the
needle. If the cell concentration is <5.0 x 105 cells per mL, the low density of cells may
prevent analyses from reaching sufficient statistical power.
20. If an inhibitory antibody, peptide or ligand is to be evaluated, incubate the diluted cells
with the antibody/peptide/ ligand for 15 min in the dark at room temperature. After
incubation, repeat Step 19 twice to wash the cells. Dilute the cells to their original volume.
21. Once diluted, keep the diluted cells on ice until i.v. injection into the CAM veins of the
chicken embryos (Table 2).
Pause Point: The cells can be left on ice for up to 2 h.

2.2.3

i.v. Injection of cancer cells into CAM veins

Timing 1 h, 2–10 min for injection per embryo
22. Assemble the microinjector (Figure 6f) by fitting an 18-gauge needle onto a 1-mL
syringe. Cut a 5–6-inch piece of Tygon tubing and carefully insert the bevel of the needle
into the bore of the tubing. Slowly slide the tubing all the way onto the rest of the needle.
23. Draw 400–500 L of cell suspension into the microinjector via the tip of the tubing.
With the needle facing upward, push the plunger to expel air from the barrel of the syringe.
Take care to prevent loss of cancer cells.
Critical step: Be careful not to inject air, as it will kill the embryo.
24. After drawing the cells and eliminating air from the microinjector, add a glass needle
(Figure 6f, g) that has been altered to have a larger bore.
Critical step: Ensure that the bore size of the needle is not too narrow. If it is too narrow,
cells will clump within the needle and form a clog. To dislodge the clog, pull back the
plunger and mix the cell suspension several times with the plunger, and then fill the tubing
and glass needle with cell suspension (Table 2).
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25. By using a dissecting scope with white-light illumination, place a day 13 embryo onto
the stage and locate any small vessels that appear to be bright red (Figure 7a). These small
vessels are veins, and they carry oxygenated blood back to the embryo because the CAM
acts as the ‘lung’ of the embryo. Vessels with darker red blood are arteries.
Critical step: Do not inject into arteries and do not inject into large-diameter veins (Figure
7a), because blood coagulation will take longer in these injection sites and the embryo will
die as a result of excessive blood loss.

Figure 7: i.v. injections of cells or lectin and setting up the extravasation efficiency
assay. (a) The microinjector is used to deliver 10–100 L of cells or diluted labeling agents
i.v. into the CAM. Initial penetration of the needle should result in the release of blood onto
the surface of the CAM, analogous to a ‘bloom’ of blood (far left panel, arrows). Slow
injection rate will result in a clear stream of fluid in the vessel (second panel from left),
and faster injection rate will result in almost full (second panel from right) to full perfusion
of the vessel (far right). Scale bars, 3 mm. (b–e) After injection of cancer cells or labeling
agents (a), 1-inch square foils are prepared (b) and placed on day 13 embryos. The
experimenter can lay a single square foil ROI per embryo (c) or three of them in a single
embryo (d). The embryo is then placed into the chicken incubator unit in which a lid that
contains a coverslip is positioned over the square foil ROI (e, top panel). A confocal upright
microscope is used to perform intravital imaging to enumerate intravascular cells or
extravasated cells (e, bottom panel). (f) When various other labeling agents are injected,
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such as lectin-DyLight 649 (purple), which labels the endothelial cell walls or vessels, and
Dextran-Alexa 555 (red), which will reveal the vessel lumen space where blood flow
occurs, they can help the investigator determine whether their cancer cells (PC-3M-LN4;
green) are intravascular, and when using a lower magnification objective (10x) the cancer
cell density throughout the CAM can be determined before extravasation efficiency
analysis. Obtaining consistent cancer cell density is important for obtaining consistent
results across different embryos. Scale bars, 25 m.

26. Glide the bore of the needle along the vein and traverse back and forth along it, until
the bore of the needle catches the CAM. Once this occurs, immediately halt the movement
of the needle and slowly raise the CAM by gently raising the needle (the CAM should pull
up with the glass needle into the shape of a pitched tent). Gently keep the CAM lifted
upward until a small ‘bloom’ of blood is seen to pop out underneath the needle (Figure 7a
inset in far-left panel).
Critical step: Remain patient when you are performing this step. The glass needle will
eventually pierce the CAM, releasing a very small amount of blood (Table 2).
27. When this ‘bloom’ of blood is observed, slowly drop the CAM and then lightly press
the plunger of the syringe. Clear fluid should enter the vessel of the CAM and flow toward
the body of the embryo.
28. Take notice of the volume markings and press down on the plunger in a light pulsatile
manner until 100 L of cell suspension is injected.
Critical step: If the needle is not cannulated within the vein, some cell suspension fluid will
leak out. If this occurs, lightly push the needle upward and toward the embryo and then
apply pressure to the plunger (Table 2).
29. After the cell suspension has been injected, remove the needle and then use rolled-up
Kimwipe to absorb all blood and cell suspension from the site of injection. This rolled-up
Kimwipe is gently laid over the injection site until the blood is soaked up.
Critical step: Do not press the Kimwipe into the CAM.

38

30. Apply 2–3 foil windows to the surface of the CAM at sites away from the injection site
(Figure 7b–d).
Critical step: Ensure that the foil windows completely adhere to the CAM surface.
31. Repeat Steps 23–31 for each embryo according to the needs of the experiment. For
each drug treatment or cell line, use N > 4–10 embryos for each group.

2.2.4

Extravasation efficiency data collection using wide-field
fluorescence microscopy

Timing: 24 h, 5 min per embryo at T = 0 and T = 24 h
Critical step: When you are performing an extravasation efficiency experiment, always
rely on N > 4–10 for each treatment/cohort/cell type. In the event that 1–2 animals die
after the T = 0 injection of cancer cells, there will at least be N = 3–7 per group for
analysis.
32. By using a wide-field fluorescence microscope and the 10x objective, count all the cells
within each foil window immediately after injection. The distribution of cancer cells across
the CAM should resemble the density seen in Figure 3f. All cells at this time point (T = 0)
are intravascular and have not extravasated into the stroma/tissue.
Critical step: Ensure that counting of all cells occurs within 1 h of Step 30 (Table 2).
33. Ensure that each foil window is counted and record the number of cells enumerated at
T = 0 on the plastic square Petri dish, directly over each individual foil window.
Critical step: Ensure that the T = 0 number is written directly over the foil window with an
alcohol-resistant felt marker when the lid is placed back on the weigh boat containing the
embryo.
34. Place all embryos back in the incubator and incubate for 24 h. (Table 2)
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35. After 24 h of incubation, either follow option A to use the wide-field fluorescence
microscope to analyze extravasation efficiency or follow option B to use the confocal
microscope to measure intravascular and extravasated cells. In addition, it is possible to
perform option B after option A.

Figure 8: Distinguishing intravascular and extravascular cancer cells in the CAM. (a–
c) By using lectin-rhodamine (red), one can easily determine whether cells (green
CellTracker dye) are present within the intravascular space (a), in the process of
extravasation (b) or extravasated (c). Lectin- rhodamine binds to the glycocalyx present on
the luminal surface of endothelial cells. White arrows point to parts of the cell that have
breached the endothelial layer. Scale bars, 10 m.
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2.2.5

Analysis of extravasation efficiency

Data-timing 1h
(i) Use the side-field fluorescence microscope to count the number of the cells within each
foil window in each embryo as in step 32.
(ii) Record each value on the lid of each embryo and ensure that each value corresponds to
each foil window as written at T=24.
(iii) After counting the number of intravascular and extravascular cancer cells present in
each window at T=0 and T=24 after i.v. injection of cancer cells, divide the number of
extravasated cells at T=24 h by the number of intravascular cells at T = 0 h (Figure 8a). If
cells in the process of extravasation are observed (Figure 8b), do not count them as
extravasated and consider them as intravascular cancer cells.
(iv) Calculate mean extravasation efficiencies for all foil windows in the embryos, as
shown in Figure 9.

Figure 9: Representative schematic of how an extravasation efficiency assay is
performed. (a) Shown is a representative set of embryos (N = 4) injected with cancer cells
treated overnight with control vehicle. Three foil ROIs are placed per embryo, and the
percentage of cells that successfully extravasate as quantified by wide-field fluorescence
microscopy in each of the foil windows is shown above the embryo. (b) Basic calculation
of extravasation efficiency as determined for each foil placed on all embryos. (c)
Representative data set for PC-3M-LN4 cells pretreated overnight with saracatinib (1, 3
and 6 M) with no recovery time prior to injection, with underlying data presented in
supplementary Data 1. Error bars represent s.e.m.
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2.2.6

Confocal microscopy of intravascular versus extravasated
cells

Timing: 30 min per embryo
(i) Inject 75 µL of diluted lectin-rhodamine with a microinjector as described in Steps 22–
29. The purpose of this step is to determine how many cells are left in the intravascular
space, as determined by lectin staining.
Critical step: Only inject the lectin-rhodamine (do not inject any cancer cells), which will
label all the endothelial cells of the CAM.
(ii) Wait for 5 min after injection of lectin-rhodamine to perform confocal microscopy.
(iii) Place the injected embryo in the imaging chamber (Figure 7e) and place the lid of the
imaging chamber such that the coverslip is situated directly over one of the foil windows.
The CAM within the foil window will adhere tightly to the coverslip of the imaging
chamber lid.
Critical step: Do not press the lid too deeply into the CAM. The coverslip of the imaging
chamber lid should be at the same height as the rest of the CAM.
(iv) Place the imaging chamber underneath the 60x objective on a confocal microscope.
Using detection protocols for green and red fluorescence signal, use confocal microscopy
to determine whether the cells are within the red vasculature (lectin-rhodamine) or whether
they have extravasated (in which case the plane of vessels will lie above individual
extravasated cells). Determine the proportion of cells that remain in the intravascular space
(Figure 8a–c). If <5% of all cells are intravascular, collect extravasation efficiency data
for the rest of the embryos using wide-field fluorescence microscopy (the high-throughput
method most commonly used for determining extravasation efficiency in cancer cells). If
>5% of cells remain in the intravascular space at T = 24 h after injection, re-evaluate at 36
h after extravasation. If <5% of cells are then intravascular, perform wide-field
fluorescence microscopy, with the assumption that any cells observed in the foil window
are extravasated cells.
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Critical step: Do not exceed T > 36 h after injection. After 36 h, cell counts may be false
(a fraction of these cells may have divided after extravasation).
(v) Dispose of all used and unused embryos by storing at −20 °C overnight before
biohazard disposal (Table 2).
Troubleshooting advice can be found in Table 2.

2.3 Timing
Steps 1 and 2, receiving fertilized eggs and first incubation period: 4–8 d
Steps 3–10, preparation of ex ovo embryos: Steps 3 and 4 are 30 min, 5 min for cracking
18 eggs Steps 11–21, preparation of cancer cells for injection: 1–3 h
Steps 22–31, i.v. injection of cancer cells into CAM veins: 1 h, 2–10 min for injection per
embryo
Steps 32–34, extravasation efficiency data collection using wide-field fluorescence
microscopy: 24 h, 5 min per embryo at T = 0 and T = 24 h
Step 35A, analysis of extravasation efficiency data: 1 h
Step 35B, confocal microscopy of intravascular versus extravasated cells: 30 min per
embryo

2.4 Anticipated results
A representative experiment in which a Src kinase inhibitor, saracatinib, is used to pretreat
PC-3M-LN4-zsGreen cells overnight at various concentrations (0, 1 M, 3 M and 6 M)
is shown in Figure 9. To determine the mean extravasation rate, we average all
extravasation efficiencies in all windows placed on all embryos. The mean value represents
the extravasation efficiency for the treatment group/cohort/cell type for the experiment.
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We do not perform mean calculations of extravasation efficiencies that are specific for each
embryo before determining the mean extravasation rates between embryos. Instead, we
consider the results attained for all foil windows as individual experiments and not specific
to the embryo. We have found that pooled analyses are more representative of the
variability between animals regardless of any variability among cells injected between
embryos, because the density of intravascular cells does not affect extravasation rates. In
our experience, most of the cells present in the CAM at T = 24 h after injection have
extravasated, with only <5% of cells visualized in the foil ROI window still present in the
intravascular space of the CAM and not yet extravasated. However, it is not well
understood whether these cells are still viable or whether they are in the process of
apoptotic cell death. When the experimenter is sufficiently trained and skilled (in terms of
injection efficiency and post-injection embryo viability rates), the number of cells present
in the ROI at T = 24 h accurately reflects the extravasation rate. It can be assumed that
these cells have successfully extravasated into the stromal space, an act of invasion that is
requisite for survival and subsequent proliferation before successful formation of a
metastatic colony in vivo.
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Table 2: Troubleshooting, tips and solutions
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Chapter 3

3

Necroptosis Mediates Cancer Cell Extravasation and
Metastasis throughout Cancer Cell Extracellular Vesicle
Release

Contents of this chapter are currently under consideration of publication in Cell Death and
Differentiation.

3.1 Introduction
Metastasis is the most lethal stage of cancer, contributing to over 90% mortality in cancer
patients1. The most invasive cancers such as prostate cancer metastasize to several distant
organs or tissues including the bone, brain, and lungs. Invasive cancer proceeds in
metastasis through multiple cellular events and signaling pathways. For example,
metastasis is comprised of different steps and each step is controlled by several cellular
molecular pathways2,3. As such, a multipronged approach is required to effectively halt
tumour metastasis4. Therefore, elucidating the underlying cellular and molecular processes
involved in different cellular events and signaling pathways in metastasis is urgently
needed.
To succeed in metastasis, single tumour cells must leave the primary tumour bed and
proceed through the metastatic cascade2,3. Leaving tumour cells enter the circulation
(intravasation), survive in the blood and lymphatic streams, arrest at a distant site, then
escape into the stromal space of a secondary organ (extravasation) to form a colony 2.
Recently, inhibition of extravasation has been suggested to be detrimental to cancer cell
surviving in the extracellular milieu, indicating that extravasation is a limiting step in the
metastatic cascade3. Although this study points to extravasation as a realistic target in
stopping cancer metastasis, other pre-existing underlying cellular mechanisms have also
been loosely explored. Hoshino et al. and Sung et al. showed that extravasating cancer
cells release extracellular vesicles (EVs) into the extracellular space5,6. EVs originate
heterogeneously from multivesicular bodies, and may include microparticles, exosomes,
oncosomes, and apoptotic bodies along a wide-size spectrum. While it is believed that
cancer cell EVs may have a functional role in cancer progression, the significance and
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potential role of EV release during extravasation have yet to be elucidated. Headley et al.
recently showed that extravasated melanoma B16F10 cells decreased in size 24 hours after
injection compared to cells at 2 hours after injection9. These studies suggest that EV release
may potentially be involved in cancer cell extravasation. Here, we investigated the
potential role of EV release in prostate cancer cell volume regulation during extravasation
and whether potential cell volume changes modulate metastatic potential.
One cellular event that may regulate EV release is cell death. Programmed cell death
processes induce cell membrane blebbing to maneuver EV biogenesis. It has also been
demonstrated that necroptosis, a form of programmed necrosis, induces intravascular
cancer cell death in a receptor-interacting serine/threonine-protein kinase 3 (RIPK3)- and
mixed lineage kinase domain-like (MLKL)-dependent manner. Gong et al. showed that
MLKL is directly involved in the scrambling of the plasma membrane to expose
phosphatidylserine (PS) and membrane bleb formation and release, which are distinct from
apoptotic blebs7. Regardless of the morphology of cells during necrosis and the secretion
of intracellular contents, the process of necroptosis allows the formation of membrane
blebs and induces EV release.
In this study, we investigated the biophysical function of EV release during cancer cell
extravasation as a measure of the metastatic efficiency of cancer cells. We discovered that
EV release led to significant cell volume reduction after extravasation, suppressing
extravasation and secondary colony formation rates. Thus, our results suggest that a
reduction in cell volume by EV release facilitates cancer cell extravasation at the cost of
reduced efficiency in forming secondary colonies. Our results also show that necroptosis
may potentially serve as a target to module EV generation, cell volume reduction,
extravasation, and secondary colony formation.

3.2 Materials and methods
Cells culture and reagents

54

Human prostate cancer cell lines PC3 and PC-3M-LN4 (ATCC) were cultured and
maintained in complete DMEM and RPMI media supplemented with 10% fetal bovine
serum, respectively. All cells were routinely tested for mycoplasma contamination. To
generate cells expressing green fluorescent proteins, vector pzsGreen-C1 (Clontech) was
stably transfected into PC-3M-LN4 and PC-3 lines with XtremeGENE HP (Roche).
Doxycycline-inducible MLKL-C-HA-3xFlag construct was kindly provided by Dr. Zhiago
Wang at the University of Texas Southwestern Medical Center. Antibodies specific for
phosphorylated MLKL (S358, ab187091) and MLKL (ab183770) were purchased from
Abcam. RIPK3, MLKL, and caspases shRNA constructs were purchased from Dr. Jason
Moffat and the Ontario Institute for Cancer Research (OICR) Genomics Facility. DyLight
649-Lectin conjugates (Lens Culinaris Agglutinin, Vector Laboratories), dextran-FITC
(Sigma Aldrich), dextran-rhodamine B (ThermoFisher Scientific), wheat germ agglutinintetramethylrhodamine (ThermoFisher Scientific), and Hoechst (ThermoFisher Scientific)
were diluted with 1x PBS (pH 7.4). Tumour necrosis factor- α (TNF-α; ThermoFisher
Scientific) was diluted into 100 μg/mL with distilled water. Staurosporine (1285, STS,
Tocris) and dimethyl fumarate (4512, DMF, Tocris) were diluted into 10 mM and 100 mM
stocks, respectively, with DMSO. Necrostatin-1 (2324, Nec-1, Torcris) and Z-VAD-fmk
(Abcam) were diluted into 50 mM and 10 mM stocks, respectively, with DMSO.
pmAmetrine-DEVD-tdTomato was purchased from Addgene.
Quantification of CAM blood vessel permeability
To quantify blood vessel permeability of chorioallantoic membranes (CAMs) at different
ages, dextran-FITC (150kDa) was injected using a microinjection needle into the CAMs
of day 9, 13, and 18 chicken embryos. Real-time imaging of the CAM was performed using
confocal microscopy at 0.5, 4, 6, 12, and 24 hours post-injection. Real-time imaging was
performed as previously described35. To calculate the mean fluorescence intensity, the
fluorescence of dextran-FITC channel in each picture was measured by ImageJ.
Quantification of cancer cell EV release in vitro and in vivo
To quantify cancer cell EV release in vitro, PC-3 zsGreen and PC-3M-LN4 zsGreen cancer
cells were cultured in DMEM and RPMI complete media with 10% FBS and grown to 80%
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confluency. Cells were cultured in serum-free medium (RPMI) with 5% exosome-depleted
serum and treated for 24 h. Treatments included: DMSO (control), STS, TNF-α, ZVADfmk, TNF-α/ZVAD-fmk/Smac mimetic, DMF, and Nec-1. Conditioned media were precentrifuged for 5 minutes at 1000 x g to remove cells and only supernatant was collected.
Samples from each well were analyzed immediately with nFC (Apogee Inc.) after
collection or stored at -80 ºC. To quantify cancer cell EVs in vivo, PC-3 zsGreen and PC3M-LN4-zsGreen cancer cells treated as indicated above were injected into the CAM of
chicken embryos at day 9, 13, or 18. After 24 hours, blood samples were collected from
the CAM of each chicken embryo and centrifuged for 30 minutes at 2,500 x g to isolate
plasma from the blood samples. The plasma samples were tested immediately by nFC after
collection or stored in -80ºC. Twenty µL of each condition media and plasma sample was
added to 180 µL of PBS and analyzed by nFC.
In vitro and in vivo FRET imaging of cancer cell EV release and caspase-3 activity
To visualize the activation of caspase-3 in PC-3M-LN4 cancer cells in vitro, cells were
stably transfected with pmAmetrine-DEVD-tdTomato (Addgene) by X-tremeGENE HP
DNA transfection reagent (Roche) for 24 h, and then selected by neomycin (Thermo
Fisher). pmAmetrine-DEVD-tdTomato-positive PC-3M-LN4 cells were resuspended in
PBS, and injected into the CAM of day 13 chicken embryos. Real-time intravital FRET
imaging of DEVD expressing cancer cells in the bloodstream was performed with an
upright resonant laser scanning confocal microscope (Nikon Fast A1R+, 60x objective) as
described previously11. Mean fluorescent intensity analysis of pmAmetrine and tdTomato
expression was performed with Image J software.
In vivo extravasation efficiency and metastatic colony formation assay
The chicken CAM assay for ex ovo metastasis and extravasation efficiency was performed
as previously described35. In brief, PC-3 and PC-3M-LN4 cells were grown to 80-90%
confluency. PC-3 and PC-3M-LN4 cancer cells were then injected intravenously into the
CAM of day 9, 13, or 18 embryos using a microinjector, and incubated in the 37 °C for 24
h. Intravascular and extravasated cells were counted in a marked area by an aluminum foil
window (1 inch x 1 inch) at T = 0 h and T = 24 h using wide-field fluorescence microscopy
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and 10x objective. At least 100 cells per region of interest were examined at T = 0 h.
Extravasation efficiency of each group per embryo was calculated by dividing the number
of extravasated cells at T = 24 h by the number of intravascular cells at T = 0 h. Then,
mean extravasation efficiencies in the embryos were calculated. Metastatic colonies in each
embryo were also counted by epifluorescence microscopy after an additional 7-day
incubation post-extravasation efficiency analysis. The Z-stack images of cells in the
bloodstream, in the course of extravasation and in the stroma were obtained by an upright
resonant laser scanning confocal microscope (Nikon Fast A1R+, 60x objective), as
described previously11.
Induction and inhibition of cancer cell death processes
PC-3 and PC-3M-LN4 cancer cell line were treated with STS, TNF-α, TNF-α/ZVADfmk/Smac mimetic (TZS), or DMF. DMSO was used as a control. To inhibit apoptosis and
necroptosis, cancer cells were treated with ZVAD-fmk and necrostatin-1, respectively.
shRNA-mediated mRNA knockdown was also used to inhibit apoptotic and necroptotic
processes. Knockdown efficiency was tested by immunostaining and immunoblotting of
RIPK3 and MLKL.
Cancer cell EV isolation
PC-3 zsGreen cells were grown to 80% confluency in complete medium. Cells were then
cultured in RPMI medium containing exosome-depleted FBS with DMSO (vehicle) and
100 μM of DMF for 48 h. The conditioned medium was collected and centrifuged at 1000
x g for 10 min to remove cellular debris and apoptotic bodies. The number of EVs (size
>100 nm) was counted by nFC.
Immunoblotting
Each group of PC-3 zsGreen cells with different treatments were lysed in NP-40
(Invitrogen) with protease inhibitor cocktail (Thermo Fisher Scientific), then rotated for 30
mins at 4 °C. Supernatant was collected after a spin at 13000 x g for 30 minutes, and the
protein concentration was determined by the BCA assay (Thermo Fisher Scientific). PC-3
zsGreen Cell and EV lysates were heated at 70 °C for 10 minutes under non-reducing
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conditions. Samples were subjected to SDS-PAGE, transferred to nitrocellulose (NC)
membranes (Thermo Fisher Scientific). and blocked with 5% bovine serum albumin in
Tris-buffered saline with 0.1% Tween-20 (TBST). Blots were incubated with indicated
primary antibodies and HRP-conjugated secondary antibodies (Invitrogen). Protein bands
were visualized using an enhanced chemiluminescent (ECL) horseradish peroxidase (HRP)
substrate (Supersignal West Pico PLUS, Thermo Scientific).
shRNA-mediated gene knockdown
The expression of both human RIPK3 and MLKL was knocked down using lentiviralexpressed shRNA.
qRT-PCR
The primers for RIPK3 were as follows: forward: 5’-GACTCCAGAGACCTCAACTTTC3’; reverse:5’-CCAGTTCATGCCTTGTCTCT-3’. The primers for MLKL were as
follows:

forward:5’AACTCAAGGCTACCAAGTGAAG3’;

reverse:5’CCAGTTCCTGAGGTGAGAGATA-3’. mRNA levels were determined by
qRT-PCR.
Statistics and Reproducibility
Comparison between groups were analyzed by Kolmogorov-Smirnov or Kruskal-Wallis
tests and multigroup comparisons were analyzed by Kruskal-Wallis test using GraphPad
Prism V6 software. Comparison between a control group and treatment groups were
analyzed by unpaired t-test using GraphPad Prism V6 software. All data were presented
as Mean ± Standard Deviation in each figure. Data with P values < 0.05, 0.01, 0.001, 0.0001
were considered significant.
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3.3 Results
3.3.1

Extravasating cancer cells experience a significant cell
volume reduction

Cancer cells confront physical stresses during extravasation8 and may be affected
significantly by the extracellular mllieu9. To reveal how efficiently invasive prostate cancer
cells extravasate into the stroma, we first measured the differential permeability of the
chicken CAM vasculature by injecting a FITC-conjugated Dextran into the CAMs10
(Figure 10). The CAM of day 9 chicken embryos showed the most permeable blood
vasculature leaking FITC-conjugated dextran more rapidly compared to day 13 and 18
CAMs (Figure 10A). Mean fluorescence intensity (MFI) analysis of dextran in the CAM
also showed that the vasculature of day 18 CAM had higher intensity of dextran over 24
hours (Figure 10B). Next, we injected PC-3M-LN4 zsGreen cells into the CAM of day 9
and 13 chicken embryos and observed similar extravasation rates (approximately 36.1%
and 34.3%), whereas PC-3M-LN4 zsGreen cells injected into the day 18 chicken embryos
exhibited extravasation rates of approximately 6.8% (Figure 11A). These differences in
extravasation capacity of PC-3M-LN4 cells injected at different times were associated with
differential metastatic colony formation (Figure 11B). This was expected as cancer cell
extravasation is a key step in metastasis. Previous studies have shown that impaired cancer
cell extravasation is detrimental to colony formation in the CAM of chicken embryos3.
Cancer cells injected into the CAM of day 9 formed the most secondary colonies (≈36
colonies on average) (Figure 11B, ii). Although extravasation rates of PC-3M-LN4 cells
in day 9 and 13 CAMs were similar, cancer cells in the CAMs of day 9 chicken embryos
formed significantly more colonies than day 13 CAMs (Figure 11B, ii). To gain an insight
into potential underlying cellular events in the differential PC-3M-LN4 zsGreen
extravasation rates, we performed confocal microscopy-based intravital imaging of PC3M-LN4 zsGreen cells before and after extravasation. Confocal imaging captured both
intravascular and extravasated PC-3M-LN4 zsGreen cells in Z-stack (Figure 11C, i-iii)
and the cell volume of each cell was measured (Figure 11C, iv). PC-3M-LN4 zsGreen
cells injected into the CAM of day 18 chicken embryos exhibited the smallest cell volume
after extravasation by losing ≈51.6% of their original cell volume, whereas cells injected
into the CAM of day 9 chicken embryos exhibited the biggest cell volume showing only

59

<10 % cell volume loss after extravasation. Meanwhile, PC-3M-LN4 zsGreen cells in the
CAM of day 13 chicken embryos exhibited ≈31.2% cell volume loss, exhibiting a moderate
level of cell volume reduction after extravasation. These results show that cancer cells
extravasation is associated with cell volume reduction but the latter can represent a limiting
factor for successful metastatic dissemination and colony formation as we observed there
is a strong correlation between an increase in cell volume reduction and decreases in cancer
cell extravasation and secondary colony formation rates.

60

Figure 10: Evaluation of vasculature permeability of the CAMs at different
embryonic development. (A) Confocal microscopy-based intravital imaging displays
different permeability of the CAM vasculature of day 9, 13, 18 chicken embryos by
showing the degree of FITC-tagged 150 kDa dextran retention. Representative images
depict that the endothelium labeled with Rhodamine-Lens culinaris agglutinin and the
lumen labeled with FITC-dextran. The CAM vasculature was imaged at 30 min, and at 4,
6, 12, 24 h points post-dextran injection. (B) Mean fluorescence intensity analysis of FITCdextran images in the CAM vasculature of day 9, 13, 18 chicken embryos at different time
points to show different vasculature permeability (n=3).
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Figure 11: The correlation between cell volume reduction and extravasation
efficiency of PC-3M-LN4 human prostate cancer cells. (A) Quantification of PC-3MLN4 zsGreen cell extravasation in the CAM. PC-3M-zsGreen cells were injected into the
CAM of day 9, 13, and 18 chicken embryos and their extravasation efficiencies were
analyzed by epifluorescence microscopy-based imaging. Injected PC-3M-LN4 zsGreen
cells were counted at T=0 and T=24 h post-injection to analyze extravasation efficiency
(n≥5 animals/group). (B) Metastatic colony formation of PC-3M-LN4 zsGreen cells in the
CAM after 4-7 days post-injection was imaged by confocal microscopy. Scale bar, 50 µm,
original magnification is 60x (i). The number of micrometastases formed by PC-3M-LN4
zsGreen cells were counted and analyzed by epifluorescence microscopy-based imaging
(n ≥ 6 animals/group) (ii). (C) Confocal microscopy-based analysis of cell volume
reduction after PC-3M-LN4 zsGreen cell extravasation. Representative images depict that
zsGreen fluorescent protein expressing PC-3M-LN4 cell gets arrested in a local capillary
(i), undergoes extravasation by forming an invadopodium (ii), and dwells in the stroma
after extravasation (iii). The endothelium and lumen of the vasculature are labeled with
Lens culinaris agglutinin-Dylight 647 (purple) and rhodamine-dextran (red) respectively.
Scale, 20 µm, original magnification is 60x. PC-3M-LN4 cell volumes in the CAM of day
9, 13, 18 chicken embryos at T=0 and T=24 h post-injection was analyzed by confocal
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microscopy (n≥47 cells/group) (iv). All error bars represent S.D. *P<0.05, **P<0.01,
***P<0.001, ****P<0.0001, unpaired t-test.

3.3.2

Invasive cancer cells spontaneously release EVs greater than
100 nm into the bloodstream during cancer cell extravasation

Emerging evidence has shown that invasive cancer cells spontaneously release EVs less
than 1000 nm both in vitro and in vivo9. Our in vivo imaging studies also revealed that
extravasating PC-3M-LN4 zsGreen cells released plasma membrane-derived EVs along a
variable size spectrum (>200 nm) into the bloodstream (Figure 12A-C). Most of the EVs
directly released from the main cell body into the bloodstream varied in size between 300
nm and 1600 nm (Figure 12C). This release was observed most frequently from
extravasating cancer cells, which were arrested within the intravascular space (Figure
12A). Intravascular cancer cells consistently generated membrane blebs that were either
retracted or released into the bloodstream as EVs (Figure 12A). Although most EVs from
the main cell body were observed in the bloodstream, we also observed that both
extravasating and extravasated cancer cells released EVs into the stromal space, providing
evidence that EV release is not only limited to an intravascular event but also to an
extravascular event (Figures 12D-G). Lastly, we observed that PC-3M-LN4 zsGreen cells
injected into the CAM of day 18 chicken embryos released the highest number of
circulating EVs (≈1.3x104 events/μL and ≈8.3x103 events/μL in average) whereas cancer
cells in day 9 showed the lowest amount of circulating EV release (≈0.61x103 events/μL
and ≈1.1 x 103 events/μL in average) (Figure 12H). Collectively, these data demonstrate
that extravasating cancer cells release EVs greater than 100 nm and ramp up EV release,
potentially to confront exterior environments, including blood vessels with reduced
permeability.
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Figure 12: Extravasating human prostate cancer cells spontaneously release large
EVs in the CAM model. (A) Representative time-lapse images of extravasating PC-3MLN4 zsGreen cells showing dynamic EV release into the bloodstream. Yellow arrows point
to EV release into the bloodstream. The blood vessel and lumen of the CAM are marked
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by Lens culinaris agglutinin-Dylight 647 (purple) and rhodamine-dextran (red),
respectively. The stroma is dark space between blood vessels. Scale, 20 µm, original
magnification is 60x. (B) Size measurement of EV released from PC-3M-LN4 zsGreen cell
from (A) by measuring EV fluorescence intensity distribution. (C) Size distribution of EV
released by extravasating PC-3M-LN4 cells. Sizes of PC-3M-LN4 EVs were measured by
fluorescence intensity distribution. (D) nFC-based size identification of PC-3M-LN4
zsGreen cell EV in plasma samples of chicken embryos. Representative cytogram shows
most PC-3M-LN4 zsGreen EVs are distributed between 180 nm and 1300 nm. LALS and
FL488 represent large-angle light scattering that measures size of EVs and fluorescent
intensities of GFP-positive EVs, respectively. (E) Representative image of EV release from
an invadopodium of extravasating PC-3M-LN4 zsGreen cell (pointed by a yellow arrow)
into the stroma. The plane underneath the blood vessel is displayed in the white box
showing that the invadopodium released the EV into the stroma. The released EV is also
pointed by a yellow arrow in XZ plane view. The blood vessel and lumen of the CAM are
marked by lectin-Dylight 647 (purple) and rhodamine-dextran, respectively. The stroma
represents dark space between blood vessels. Scale bar, 20 µm, original magnification is
60x. (F) Size measurement of EV released from PC-3M-LN4 zsGreen cell from (E) by
measuring EV fluorescence intensity distribution. (G) EV release into the stroma by
extravasated PC-3M-LN4 zsGreen cell. PC-3M-LN4 zsGreen cell EVs (Green) released
into the stroma are pointed with yellow arrows. Blood vessel and lumen are marked by
lectin-Dylight 647 (purple) and rhodamine-dextran (red), respectively. The stroma is dark
space between blood vessels. Scale bar, 20 µm, original magnification is 60x. (H) Size
measurement of PC-3M-LN4 zsGreen cell EV release into the stroma by measuring EV
fluorescence intensity distribution. (I) nFC based quantification of circulating PC-3M-LN4
zsGreen cell EVs in plasma samples of chicken embryos. PC-3M-LN4 cells were injected
into the CAM of day 9, 13, 18 chicken embryos and the blood of all chicken embryos were
collected at T=24 post-injection. All error bars represent S.D. ***P<0.05, unpaired t-test.
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3.3.3

Cancer cell EV generation during cancer cell extravasation is
not predominantly regulated by apoptosis

We investigated whether apoptosis is responsible for EV biogenesis from extravasating
cancer cells, because apoptosis mainly leads to cell membrane blebbing, which is a source
of EV biogenesis. To induce apoptosis in cancer cells, PC-3M-LN4 cells were treated with
1 μM of staurosporine (STS). STS is a cell-permeable alkaloid that readily induces
apoptotic cell death. STS-treated PC-3M-LN4 cells displayed high mAmetrine and low
tdTomato fluorescence signals whereas vehicle-treated PC-3M-LN4 cells showed both
high mAmetrine and tdTomato fluorescence signals (Figure 13A). In agreement with a
previous study by Ai et al., the mean fluorescent intensity ratios (MFI between
tdTomato:mAmetrine) of control and apoptotic PC-3M-LN4 cells were 1:1.99 and 1:5.32
respectively11 (Figure 13B). Compared to in vitro images of mAmetrine and tdTomato
expression in healthy and apoptotic cells, intravital FRET imaging of cancer cell EV
release revealed that not only the main cell body had both high mAmetrine and tdTomato
fluorescence signals but also the released EV did (Figure 13C; marked by yellow arrows).
The fluorescent intensity of each channel showed that the MFI of EV release in PC-3MLN4 cells (1:2.13) was closer to that of intact PC-3M-LN4 cells than apoptotic PC-3MLN4 cells (1:5.32) (Figure 13D). These data show that other cellular mechanisms may
dominantly maneuver the EV generation and release, however this cell death pathway is
still involved in the stimulation of EV release.
To build on our results, we exposed PC-3 zsGreen cells to tumour necrosis factor-α (TNFα) or pan-caspase inhibitor ZVAD-fmk (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]fluoromethylketone) and measured EV release. TNF-α (2-10 ng/mL) increased EV release
in vitro (>2 folds), whereas caspase inhibitor ZVAD-fmk (3&5μM) showed an
approximately 2-fold decrease in EV release (Figure 14A). These results were
recapitulated by the quantification of EV release in vivo: TNF-α (5 ng/mL) treated PC-3
zsGreen cells exhibited an increase in EV release, compared to vehicle treated cells (Figure
14B). TNF-α (1 ng/mL) treated PC-3 zsGreen cells also showed a significant decrease in
their extravasation rates (≈30%), compared to vehicle (≈50%) (Figure 14C). This readout
was mirrored by STS (65 and 130 nM) showing significant decreases in PC-3 zsGreen cell
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extravasation rates (<30%) (Figure 14D). Inhibiting apoptosis by ZVAD-fmk (3, 5μM)
significantly increased extravasation rates (>60%) (Figure 14E), although that apoptosis
inhibition by shRNA-mediated caspase-3 knockdown did not show a significant alteration
in extravasation rates (Figure 14F). These results suggest that apoptotic signaling
negatively affects cancer cell extravasation, possibly through increasing EV release.
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Figure 13: FRET imaging of extracellular vesicle release by mAmetrin-DEVDtdTomato expressing cancer cells. (A) Representative confocal imaging of caspase-3
activation in apoptotic and non-apoptotic PC-3M-LN4 cells. PC-3M-LN4 cells were
treated with vehicle (DMSO) or staurosporine (1 μM) for 24 hours. Scale bar, 20 µm,
original magnification is 60x. (B) Mean fluorescence intensity analysis of mAmetrine and
tdTomato in PC-3M-LN4 cells treated with vehicle (DMSO), 1 μM or 2 μM of
staurosporine (STS) for 24 h. Images of PC-3M-LN4 cells under each treatment (n≥6
cells/group) were taken by confocal microscopy and fluorescent intensities of mAmetrine
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and tdTomato in each cell were analyzed by ImageJ. (C) Intravital FRET imaging of
caspase-3 levels during in vivo PC-3M-LN4 cell EV release, as assessed by mAmetrineDEVD-tdTomato fluorescence. PC-3M-LN4 cells were injected into day 13 chicken
embryos for the intravital FRET imaging. A yellow arrow indicates the EV release from
the main cell body. Scale bar, 20 µm, original magnification is 60x. (D) The comparison
of mean fluorescent intensity ratio (MFI) of mAmetrin and tdTomato expressions in EV
releasing PC-3M-LN4 cells with non-apoptotic (with DMSO) and apoptotic (with 1 μM
STS) PC-3M-LN4 cells. All error bars represent S.D. **P<0.01, ***P<0.001, unpaired
student t-test.
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Figure 14: The effect of apoptosis on PC-3 cell EV release and extravasation. (A) Proapoptotic and anti-apoptotic effects to PC-3 cell EV release in vitro. PC-3 zsGreen cells
were treated with TNF-α (1, 2, 5, 10 ng/mL) or ZVAD-fmk (3, 5μM) for 24 h. The
conditioned medium was analyzed by nFC to quantify the EV release (n=3 independent
experiments). (B) Effect of apoptotic PC-3 zsGreen cells in vivo. PC-3 zsGreen cells were
treated with DMF or TNF-α (5, 10 ng/mL) and injected in (n≥4 animals/group). The
conditioned medium of PC-3 zsGreen cells for each treatment was analyzed by nFC. (C)
Pro-apoptotic effects of TNF-α (1 ng/mL and 2 ng/mL) on PC-3 zsGreen cancer cell
extravasation efficiency. PC-3 zsGreen cells with each treatment were injected and
extravasation efficiency was measured by counting the number of cells at T=0 and T=24
(n≥7 animal/group). (D) Pro-apoptotic effects of STS (65 nM and 130 nM) on PC-3
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zsGreen cancer cell extravasation efficiency. Injected PC-3 zsGreen upon each treatment
were counted at T=0 and T=24 (n≥9 animal/group). (E) Anti-apoptotic effects of ZVADfmk on PC-3 zsGreen cell extravasation efficiency. PC-3 zsGreens cells treated with
ZVAD-fmk (3μM and 5μM) for 24 h were injected and the numbers of PC-3 cells were
counted at T=0 and T=24 (n≥14 animal/group) to analyze PC-3 cell extravasation
efficiency. (F) The effect of shRNA derived caspase-3 knockdown on PC-3 cancer cell
extravasation efficiency. shRNA targeting caspase-3 introduced PC-3 cells were injected
into the CAM of day 13 and PC-3 cells were counted at T=0 and T=24 to evaluate PC-3
cell extravasation efficiency (n≥14 animal/group). All error bars represent S.D. *P<0.05,
**P<0.01, ***P<0.001, unpaired student t-test.

3.3.4

Necroptosis-induced EV release in human prostate cancer
cells

Emerging studies have shown that a combination of tumour necrosis factor-α (TNF-α) with
ZVAD-fmk (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone) and
Smac mimetic (small-molecule inhibitor of apoptosis antagonists) robustly induces
necroptosis12. In addition, dimethyl fumarate (DMF, Tecifera) has been highlighted as a
promising necroptosis inducer and is already approved by the FDA13. Using this platform,
we tested whether necroptosis induces EV release in prostate cancer cells. As a proxy for
necroptosis induction, we measured the levels of mixed lineage kinase domain-like
(MLKL), a critical regulator of necroptotic cell death. PC-3 cells treated with TNF-α
(100ng/mL), ZVAD-fmk (20μM), Smac mimetic (100 nM) or TZS (combination), and
DMF (100μM) showed significant increases in MLKL mRNA levels compared to vehicle
treated PC-3 cells (Figure 15A). The levels of MLKL mRNA in TZS- and DMF-treated
PC-3 cells were as high as doxycycline-inducible MLKL overexpressing PC-3 cells (>4
folds) (Figure 15A, 17F). PC-3 cells overexpressing MLKL treated with TZS exhibited
the highest MLKL and phosphorylated MLKL levels (Figure 15B). Although TZS or DMF
treated PC-3 cells showed increased MLKL and phosphorylated MLKL, DMF treatment
induced significantly higher phosphorylated MLKL compared to both TZS and vehicle
(Figure 15B). MLKL-knockdown in PC-3 cells showed a significant decrease in both
mRNA and protein levels of MLKL (Figure 15A, B). We then investigated the effect of
DMF-induced necroptosis on cancer cell EV release during extravasation. nFC analysis of
conditioned medium of PC-3 cells treated with TZS and DMF showed that both TZS and
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DMF-mediated necroptosis induced PC-3 EV release. However, DMF treated PC-3
zsGreen cells exhibited greater than a 3-fold-increase in the number of EV release in vitro
(Figure 15C, D). Next, TZS treated PC-3 cells were injected into the CAM of day 13
chicken embryos. After 24 hours post-injection, both TZS and DMF treatments induced
significant PC-3 zsGreen cell EV release compared to vehicle treated PC-3 zsGreen cells,
with DMF treatment causing a higher increase (> 3 fold) in vivo (Figure 16A, B). These
results show that DMF induces necroptosis by increasing MLKL and phosphorylated
MLKL levels in PC-3 cells and causes necroptosis-mediated PC-3 cell EV release. These
results also suggest that DMF-induced cancer cell necroptosis can potentially increase
cancer cell EV release during extravasation, more so than TZS treatment.
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Figure 15: DMF induced necroptosis pathway is involved in cancer cell EV release.
(A) Real-time PCR-based mRNA quantification of MLKL gene in TZS and DMF treated
PC-3 cells (n=2 independent experiments). RPLP0 gene was used as a housekeeping gene
for normalization. (B) Protein quantification of MLKL, phosphorylated MLKL, RIPK3,
and active caspase-3 in PC-3 cells with TZS, DMF, and MLKL knockdown and
overexpression (n=2 independent experiments). Lysates from PC-3 cells in each treatment
were subjected to western blotting. (C) nFC based quantification of in vitro PC-3 zsGreen
cell EV release with TZS treatment. (n=3 independent experiments) (D) Quantification of
DMF (100 μM) treated PC-3 zsGreen cell EV release in vitro by nFC-based analysis (n=3
independent experiments). All error bars represent S.D. Unpaired t-test.
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Figure 16: DMF induced PC-3 cell necroptosis, increased EV release, and reduced
PC-3 metastasis. (A) nFC analysis of in vivo EV release from PC-3 zsGreen cells treated
with DMSO and TZS in the CAM. PC-3 zsGreen cells were injected into the CAM of day
13 chicken embryos. Plasma samples from each chicken embryo was collected at T=24 h
post-injection (n=10 animals/experiments). (B) nFC analysis of in vivo EV release from
PC-3 zsGreen cells treated with DMSO and 100μM of DMF. Plasma samples from each
chicken embryo was collected at T=24 h post-injection (n≥6 animals/group). PC-3 zsGreen
cells with each treatment were injected into the CAM of day 13 chicken embryos (n≥6
animals/group). (C) Confocal imaging-based cell volume change analysis of PC-3 zsGreen
cell under DMSO, Nec-1 (50 μM) and DMF (100 μM) treatments (n≥24 cells/group) after
injections into the day 13 chicken embryos. PC-3 cells with each treatment were imaged at
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T=0 and T=24 h post-injection. (D) In vivo PC-3 cell extravasation assay under Nec-1
(50μM) and DMF (100μM) treatments. PC-3 zsGreen cells with each treatment injected
into the CAM (n≥6 animals/group) of day 13 chicken embryo. The numbers of PC-3 cells
were counted at T=0 and T=24 h post-injection. (E) Epifluorescence imaging-based in vivo
metastatic colony assay of PC-3 zsGreen cell under necroptosis in the CAM.
Representative images metastatic colony formations by DMSO and DMF (100μM) treated
PC-3 zsGreen cells. Scale bar 20 µm, original magnification is 60x. PC-3 zsGreen cells
with each treatment injected into the CAM of day 9 chicken embryo and secondary
colonies were quantified after 4 days (n=5 animals/group). All error bars represent S.D.
*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. Unpaired t-tests.

3.3.5

Increased necroptosis-derived EV release is detrimental to
the metastatic efficiency of invasive cancer cells

Our studies showing necroptosis-mediated EV release prompted us to investigate whether
this process is associated with cell volume changes, extravasation rates and metastatic
potential. To test this, we treated cells with vehicle, DMF, and necrostatin-1, an inhibitor
of necroptosis. Our results show that differential amounts of EV release induce different
levels of cell volume reduction after extravasation. The DMF (100 μM) group showed the
most cell volume loss (≈51.0%) compared to the vehicle group (≈36.1%), whereas
necrostatin-1 treated PC-3 zsGreen cells showed the least cell volume loss (≈25.2%)
(Figure 16C). As PC-3 zsGreen cancer cells lost more cell volume due to excessive EV
release under DMF treatment, DMF treated PC-3 zsGreen cells exhibited a significant
decrease in their extravasation rates (≈28.8%) after 24 hours in the CAM compared to
vehicle treated PC-3 zsGreen cells. However, PC-3 zsGreen cells with necrostatin-1
treatment exhibited a significant increase in extravasation efficiency (≈63.7%) (Figure
16D). DMF-induced necroptosis decreased not only the number (≈ 0.75-fold), but also the
magnitude (≈ 0.5-fold) of metastatic colony formation by PC-3 zsGreen cells in the CAM
(Figure 16E). To recapitulate the effects of necrostatin-1 on cancer cell necroptosis during
extravasation, we determined whether knocking down RIPK3 and MLKL by shRNAs
significantly affects cancer cell extravasation. Firstly, knockdown of RIPK3 and MLKL
were very efficient in reducing the levels of RIPK3 and MLKL mRNA and protein in PC3 cells (Figure 17A). shRNA-mediated RIPK3 and MLKL knockdown resulted in a
decrease in the expression of RIPK3 and MLKL (Figure 17B). Although knockdown of
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RIPK3 did not affect PC-3 zsGreen cell EV release, knockdown of MLKL significantly
reduced the number of EVs released as compared to the control group (Figure 17C).
However, the knockdown of both RIPK3 and MLKL led to a significant increase (≈61.9%
and ≈56.5%, respectively) in extravasation rates of PC-3 zsGreen cells compared to the
control group (≈43.5%) (Figure 17D). This further confirmed that intravascular
necroptosis significantly regulated cancer cell extravasation. The knockdown of MLKL led
to an increase in metastatic colony formation (≈31 micrometastases) whereas the RIPK3
knockdown did not improve the metastatic colony formation of PC-3 zsGreen cells (≈18
micrometastases) (Figure 17E).
Doxycycline-inducible MLKL overexpression in PC-3 cells was confirmed by measuring
mRNA and protein levels, showing increases in both MLKL and phosphorylated MLKL
(Figure 17F, G). In addition, MLKL overexpression with TZS treatment showed a
significant decrease in PC-3 cell extravasation efficiency (Figure 17H). Altogether, our
results show that cancer cell necroptosis promotes cell volume reduction by inducing
excessive EV release during extravasation, resulting in a significant decrease in cancer cell
metastatic capacity.
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Figure 17: Genetic modulation of necroptosis and the corresponding changes in PC3 EV release and metastatic potential. (A) qRT-PCR analysis of RIPK3 and MLKL
mRNA in PC-3 cells. PC-3 cells were transduced with lentivirus expressing shRNA
targeting RIPK3 and MLKL (n=3 independent experiments). (B) MLKL proteins in PC-3
cells expressing RIPK3 and MLKL shRNA. (C) nFC based quantification of shRNA
expressing PC-3 zsGreen cell EV release. PC-3 zsGreen cells were injected into the CAM
of day 13 chicken embryos. Plasma samples of chicken embryos were collected at T=24 h
post injection (n≥4 animals/group) (D) In vivo extravasation assay of PC-3 zsGreen with
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RIPK3 and MLKL shRNA. PC-3 cells were injected into the CAM of day 13 chicken
embryos (n≥8 animals/group). The number of extravasated cells at T=0 and T=24 h postinjection counted by epifluorescence microscopy. (E) In vivo metastatic colony assay of
PC-3 zsGreen shRNA clones in the CAM of chicken embryo (n≥6 animals/group). All PC3 shRNA clones were injected into the CAM of day 13 chicken embryos and the number
of extravasated cells on 7th day post-injection was analyzed by epifluorescence
microscopy. (F) qRT-PCR analysis of MLKL mRNA in MLKL overexpressing PC-3 cells
(n=2 independent experiments). PC-3 cells were stably transfected with a doxycyclineinducible MLKL expressing construct. RPLP0 was used as a housekeeping gene. (G)
MLKL protein quantification. Doxycycline-inducible MLKL overexpressing PC-3 cells
treated with PBS, doxycycline only, and doxycycline with TZS were subjected to western
blot for MLKL. (H) In vivo extravasation assay of MLKL-overexpressing PC-3 zsGreen
cells. Control vector (control) and MLKL overexpressing PC-3 cells were injected into the
CAM of day 13 chicken embryos (n≥3 animals/group). The number of extravasated cells
at T=0 and T=24 h post-injection counted by epifluorescence microscopy. All error bars
represent S.D. *P<0.05. Unpaired t-tests.
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3.4 Discussion
Cancer cell volume reduction may be a prerequisite to a metastatic phenotype of
extravasating cancer cells since endothelial integrity (i.e. gap junctions) of the blood vessel
is a barrier to successful extravasation8, 16, 17. Due to the size restriction of cancer cells in
the transendothelial space, cell volume reduction by EV release8, 17, 18 may be a strategy
by the cancer cells to succeed in extravasation, as evidenced by our studies (Figures 11C).
Even if cells succeed in crossing the endothelial wall, the stromal environment, comprised
of connective tissues, is another barrier to extravasation. The stroma creates an ideal niche
for cancer cell growth and progression of secondary colonies19-27, but extravasating cancer
cells also confront spatial restrictions when entering the stroma. Our in vivo extravasation
assays with the CAM of chicken embryos showed that fluorescently labeled PC-3M-LN4
cells spent over 24 hours to extravasate into the stroma and continuously released large
EVs into the bloodstream (Figures 11C and 12A, 12C, 12H). While it was previously
unclear whether large EV release reduces cell volume during extravasation, our results
(Figures 11C and 12H) provide evidence showing that an increase in large EV release is
correlated with a decrease in cancer cell volume after extravasation. As previous studies
showed that cancer cells have a higher chance of extravasation if they rapidly extravasate
into the stroma, cells would reduce cell volume by releasing excessive EVs into the
bloodstream8, 17, 18. A recent study by Lyons et al. showed that most invasive cancers
acquire a smaller cell volume over time28. In addition, using intravital imaging (Figure
11C), we observed that most cancer cells in the stroma exhibit reduced cell volume and
size, potentially allowing the cancer cells to extravasate. When cancer cells reduced their
cell volume (Figure 11C), extravasation efficiency significantly decreased (Figure 11D).
Thus, we suggest that a reduction in cancer cell volume by cancer cell EV release facilitates
cancer cell extravasation, but excessive EV release is counterproductive to metastatic
capacity. As such, future studies regarding the cellular processes of cancer cell volume
reduction during extravasation are warranted.
Various cellular processes are involved in driving heterogeneity in EV biogenesis. In this
study, we focused on determining key cellular pathway targets in which membrane-derived
EVs are initiated. A reliable source of cell membrane blebbing is during programmed cell
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death that includes apoptosis and necroptosis. Although cancer cells spread to distant sites
throughout the circulatory system, the extracellular milieu of cancer cells in the
bloodstream is detrimental to cell viability and successful extravasation. Most intravascular
cancer cells must be trapped in the capillaries near secondary organs in order to be
successful in extravasation, though they cannot escape from cell death upon detaching from
endothelial cells or from geometrical pressure29. Apoptosis releases apoptotic bodies which
can be a principal mechanism for intravascular programmed cancer cell death. We
recapitulated the study of Dr. Weiss in 1985 by performing intravital imaging of
extravasating cancer cells in the CAM. We initially hypothesized that apoptosis may be the
main cue of cancer cell membrane blebbing and EV release since intravascular cancer cells
are exposed to many apoptosis inducing factors (for example, reactive oxygen species,
nutrient accessibility, immune attack). While apoptotic intravascular cancer cells exhibited
increased circulating EVs (Figure 14A, B), real time FRET imaging of EV-releasing
cancer cells in the bloodstream did not show elevated caspase-3 activity, while increased
activity was noted in vitro (Figures 13A, B). As EV-releasing cancer cells maintained the
fluorescence of both mAmetrine and tdTomato without FRET quenching, the results are
indicative of a lack of caspase-3 activity (Figures 13C, D)11.
Regardless of whether EV release is regulated by apoptosis, intravascular cancer cells still
exhibit cell death in the bloodstream. The lack of a real-time necroptosis reporter still
leaves the origin of cancer cell EV release obscure. A recent study provides evidence that
membrane blebbing and release are initiated by phosphorylated MLKL7. Numerous cancer
cell types express basal RIPK3 and MLKL that can initiate membrane blebbing30.
Circulating necroptosis inducing factors, such as TNF-α, might induce intravascular cancer
cell necroptosis31,32. Here, we also introduced DMF as a potential necroptosis inducer13
showing increased levels of MLKL and phosphorylated MLKL (Figure 15B). Confronting
intravascular necroptosis, inevitably some cancer cells could survive and succeed in
extravasation to form metastatic colonies as evidence from our studies (Figures 15D,E).
One possible cellular process involved in EV release may be the removal of detrimental
proteins such as MLKL. It is widely known that endosome-derived EVs require ESCRTIII machinery33. However, release of large EVs containing MLKL is also facilitated by the
recruitment of ESCRT-III complex, comprised of CHMP2A and CHMP4B7. Such
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discharge of EVs containing MLKL may not only remove a detrimental protein, but may
also defer MLKL induced-plasma membrane damage7,34. Regardless of the potential
plasma membrane recovery mechanism described previously, our studies show that an
increase in PC-3 EV release by DMF correlates with cell volume reduction, and a failure
of extravasation and metastatic colony formation. Knockdown of MLKL led to a
significant decrease in PC-3 cell EV generation and implicated that PC-3 cells may avoid
excessive cell volume reduction which significantly reduces extravasation and metastatic
colony formation (Figure 16). We do note that the expression of RIPK3 and MLKL has
yet to be tracked in real time during EV release.
Overall, since many invasive cancers are apoptosis-resistant, it is likely advantageous to
exploit the nature of necroptosis, in which more cancer cell EV release can be stimulated,
to sensitize cancer cells to intravascular death before they cross the endothelial border.
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Chapter 4

4

Conclusions and future directions

4.1 Quantification of Cancer Cell Extravasation In Vivo
4.1.1

Summary of findings and conclusions

The key findings from the first part (chapter 3) of my thesis show morphological changes
of cancer cells in the course of extravasation in the chorioallantoic membrane (CAM) of
chicken embryo. The observation of morphological changes also permits to assess
precisely whether cancer cells succeed in extravasation and perform powerful
quantification of cancer cell extravasation as well. Chapter 3 ultimately shows the CAM
model is suitable for evaluation of potential pharmacological or genetic treatments on anticancer extravasation in vivo in a high-throughput manner. Many substantial studies already
proved its reliability and reproducibility as a better animal model system by collaborating
with us.
Research into methods that could allow the investigation of the key cellular steps in
metastasis initiated the body of this work. This work established not only a robust animal
model for the quantification of cancer cell extravasation, but also a suitable system to
observe underlying cellular and molecular events during cancer metastasis. The analysis of
cell extravasation efficiency directly links to the evaluation of cancer cell invasiveness.
Previous quantification methods of cancer cell extravasation have relied heavily on the
mouse or zebrafish model as in vivo systems or the matrigel degradation assay as an in
vitro system. In chapter 3, I introduced the CAM of chicken embryo as providing all the
advantages of the CAM model and resolving limitations associated with the previous
models. In addition, the optimization of the CAM-based quantification of cancer cell
extravasation has provided researchers with a highly effective model in the field.
The CAM model is accessible to confocal-based intravital imaging techniques to visualize
cancer cell extravasation from the blood vessels and into the stroma. The only prerequisite
technique is an intravenous injection of cancer cells, and fluorophore-conjugated dextrans
(to highlight vessel lumens) and lectins (binding to glycocalyx on the endothelial cell wall).
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I investigated which embryonic day is suitable to inject cancer cells and monitored rapid
cancer cell extravasation in the CAM. The CAM of day 13 chicken embryos provided a
well-developed vasculature and allowed cancer cells to extravasate within 2-6 h postinjection, compared to older chicken embryos ( day 14 chicken embryos, > 9 hours postinjection). In chapter 4, the vascular permeability of the vasculature of day 9, 13, 18
chicken embryos was evaluated by measuring the level of FITC-dextran retention. This
observation was also evaluated by another group (Willetts et al.) and published following
my Nature protocols article1,2, highlighting the importance as well as the reproducibility of
my work.
The CAM assay has been used by several of our collaborators to quantify different cancer
cell lines following different genetic and pharmacological treatments. A study by Mesci et
al. showed that MDA-MB-231 cells (MDA.330-3p) transfected with microRNA miR-3303p exhibit a significant decrease in extravasation efficiency and metastatic colony
formation, using the CAM assay. Intravital imaging of MDA.330-3p cells in the CAM also
showed impaired invadopodia formation, suggestive of reduced invasiveness3. Another
study by Stender et al. using the CAM assay showed that MCF-7 breast cancer cells with
estrogen receptor- knocked out exhibit significantly decreased extravasation efficiency in
response to interleukin-1 and TNF-4. Lastly, Tornin et al. reported that FUS-CHOP, an
oncogene that increases a metastatic potential, significantly increases extravasation
efficiency of bone marrow mesenchymal stem cells (BM-MSCs)5. These studies highlight
the utility of the CAM extravasation model for quantification purposes. Although my work
optimized the protocol of the CAM-based cancer extravasation method, such a tool may
also be used to examine intravasation, in vivo EV release from circulating tumor cells and
cells at the primary tumor sites. Lastly, the CAM model can be utilized to study the
interaction between tumor cells and immune cells. Therefore, the model provides a highly
valuable experimental platform.
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4.1.2
4.1.2.1

Future directions for CAM modeling
Tracking tumor EV release and EV transfer in xenografted
tumors

An emerging concept that would be important to investigate in future studies is EV transfer
between cells. Very recently, EVs derived from glioma cells were shown to deliver
oncogenes such as c-myc and EGF-RvIII to donor cells, inducing mitogen-activated
protein kinase (MAPK) and Akt pathway and promoting anchorage-independent cell
growth and survival6. A study by Yu et al. also showed that EVs from colorectal carcinoma
could transfer tissue factor (TF) that activated K-RAS in donor cells and contributed to
tumorigenic and angiogenic phenotype7. Conversely, Luhtala and Hunter showed that KRas embedding U-87MG human glioblastoma cell EV transfer did not evoke K-Ras
function in donor cells8. EVs attaching to donor cells were found to be less than 2% and
only 0.08-0.10% of total K-Ras fusion proteins were shown to be released into EVs. Instead
of that donor cells taking up EVs containing oncogenes, this study suggested that U-87MG
EVs might affect cancer cell migration by providing more anchors or increasing
chemoattractant release. To validate whether cancer cells deliver EV cargoes to donor cells
and induce oncogene functions, a model system providing physiological environment is
required. To this end, I propose implanting invasive cancer cell lines such as PC-3, MDAMB-231 cells with or without GFP expression in distant or close proximity. After a week
to allow tumor growth, we may collect tumors for histological analyses and assessment of
protein levels by immunoblotting. Once we confirm the presence of protein transfer by
donor EVs, we can perform a proteomic analysis to investigate whether the types of
transferred proteins are their functional significances from pathway analysis. We may also
perform an intravital imaging of tumor EV transfer. This may be achieved through
implanting GFP- and RFP-expressing cells and observing GFP or RFP EV transfers.
Studies by Verweij et al. and Hyenne et al. showed that cancer cell-derived EVs injected
into the blood vessels of zebrafish embryos were captured by the endothelium and
circulating macrophages9,10. These studies did not report direct EV-derived oncogene
transfer to recipient cells but suggested that cancer cell-derived EVs may reprogram the
fate of macrophages to adopt a pro-inflammatory phenotype. Since the CAM provides a
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systemic environment for tumors and circulating EVs, the platform may yield valuable
information on cancer cell EV transfer.

4.1.2.2

Studying tumor intravasation

Studying cancer cell intravasation mostly relies on the mouse xenograft model in which
human cells or tissues are implanted in mice. Studies by Deryugina and Kiosses show
human fibrosarcoma cell variants with low and high invasiveness (HT-lo/diss and HThigh/diss, respectively) exhibit different levels of cancer metastasis when implanted in
mice11. Although the researchers noted intravasating cells with low and high levels of
invasiveness, advanced imaging analyses were lacking. Specifically, techniques to process
acquired pictures and determine the score of cancer cell intravasation would have provided
greater knowledge. Peng et al. coupled an in vitro transwell system and a mouse
subcutaneous xenograft model to study the degree of cancer cell intravasation12. They
plated human microvascular endothelial cells at the bottom of a transwell and then overlaid
human breast cancer which induced endothelial permeability. They also implanted MDAMB-231 subcutaneously in mice and then intravenously administered TiO2 nanoparticles
to induce vessel permeability. The combination of the in vivo and in vitro assays was used
to quantify the degree of cancer cell intravasation. One could argue that real-time imaging
of cancer cell intravasation would circumvent the challenges of coupling multiple systems
and drawing limited conclusions. Another limitation of these studies mentioned above, is
that the currently used models do not allow for simultaneous assessment of morphological
changes in cells such as invadopodia formation, which is required for intravasation. The
CAM model is a robust model to observe any underlying cellular events such as cell
shape/size changes, invadopodia formation, and EV release during intravasation by using
confocal microscopy-based intravital imaging. To establish the CAM model for
quantification of cancer intravasation, GFP-expressing cancer cells with different degree
of invasiveness may be selected. For example, human prostate cancer cell lines PC-3, DU145, and LnCap show the highest, medium, lowest invasiveness, respectively, and may
provide useful information. The cells may then be implanted on the CAM of day 9 chicken
embryos which will provide the highest permeability to the CAM vasculature. Then, we
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can incubate the CAM until tumors are visible ( 4-7 days). Imaging the CAM vasculature
near the tumors will allow us to evaluate the presence of intravasated cancer cells. Once
we confirm the presence of cancer cells in the blood stream, we can also perform a realtime imaging of the edges of the tumors to capture the events of cancer cell intravasation.
Quantification of cancer cell intravasation can be performed by capturing pictures of the
CAM vasculature surrounding the primary tumors followed by counting GFP positive
individual cancer cells.

4.1.2.3

Developing a humanized CAM model to study tumor and
immune cell interaction

Another exciting future study will be to use the CAM model to investigate tumor-immune
cell interaction. Currently, immune system interaction with tumors is commonly studied in
mice. Yamaguchi et al. have cultured peripheral blood mononuclear cell-derived dendritic
cells, melanoma antigen recognizing T cells (MART-Ts), and human melanoma tumor
infiltrating lymphocytes and introduced the cells into non-obese diabetic mice13. In this
model, immune cells proliferated and exhibited anti-tumor activity when implanted in
mice. Likewise, humanized mice are also being widely used to develop cancer
immunotherapy by using patient-derived xenografts (PDXs)14. However, generating these
humanized mice is expensive and time-consuming. Perhaps the CAM model may be used
to study these cell-cell interactions in a cost-effective and high-throughput manner. To
achieve this, we can possibly introduce human peripheral blood mononuclear cells via
intravenous injection in the CAM model. We can then collect blood samples at different
time points post-injection to examine the survival of injected cells. Once we establish such
a cell transfer to be feasible, tumor cells or portions of tumor tissues may be implanted.
This study may allow us to perform immunohistochemistry to evaluate the presence of
tumor infiltrating lymphocytes. This study may also lead to a next generation animal model
to study potential immunotherapy.
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4.2 Necroptosis: A Key Mediator of Cancer Cell
Extracellular Vesicle Biogenesis and Regulator of
Cancer extravasation
4.2.1

Summary of findings and conclusions

The key findings from the second part of my thesis show the two main events during cancer
cell extravasation: 1) the reduction of cancer cell volume during cancer cell extravasation
as an invasive phenotype of extravasating cancer cells, and 2) cancer cell EV release as a
potential cellular process leading to the cell volume loss. Although the cell volume
reduction at certain threshold may help cancer cells execute to extravasate, excessive cell
volume loss is detrimental to cancer cell metastasis. In addition, the body of this work
evidences that necroptosis is a potential trigger to induce excessive cancer cell EV release
leading to subsequent excessive cell volume reduction, resulting in a failure in cancer
metastasis.
Studying underlying events during cancer cell extravasation may lead to the discovery of
new targets to stop cancer metastasis. In chapter 4, I showed that cancer cells reduce cell
volume after extravasation. Confocal microscopy revealed that cancer cells spontaneously
release large EVs into the blood stream. My results also suggest that there is a threshold
for EV release generating subsequent desired outcomes for the cancer cells. Specifically,
cancer cell EV release may reduce cell volumes, facilitating endothelial transmigration and
extravasation. Increasing further EV release may reduce extravasation by inducing cell
death. Although other researchers have focused on what signal these EVs may be providing
to bystander cells, my research focused on the direct phenotypic modulation of cancer cell
through EV release.
Research into cancer cell EVs has led to seminal findings, including the observation that
vascular endothelial cells may be activated by taking up cancer cell-derived EVs and
regulate angiogenesis and vascular permeability. Both vascular permeability and
angiogenesis are essential for tumor growth, at least in solid tumors. A study by Zeng et
al. showed that cancer cell-derived large EVs contained miR-25-3p that increased the
expression of vascular endothelial growth factor receptor-2 (VEGFR2) in endothelial cells.
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Such an increase contributed to vascular permeability and angiogenesis15. Similarly,
Paggeti et al. reported that leukemia cell-derived EVs induce proliferation in normal
endothelial cells, and increase invasiveness by remodeling of the actin cytoskeleton16.
Schillaci et al. also showed that metastatic colorectal cancer cell (SW620)-derived EVs
confer an invasive phenotype in non-metastatic colorectal cancer cells (SW480) and human
endothelial cells (HUVEC) by activating the RhoA/ROCK pathway17. Cancer cell EVs are
also believed to induce endothelial-to-mesenchymal transition (EndMT) to facilitate tumor
growth18. These studies underscore the importance of cancer-derived EVs in promoting
tumor growth and metastasis.
Cell phenotype changes are also important for cancer progression. McGrail et al.
demonstrated that more invasive cancer cells are more contractile19. Bakal et al. showed
that highly invasive cancer cells had active changes in cytoskeletal gene expression,
resulting in morphologic changes20. Based on these observations, Lyons et al.
demonstrated the morphologic differences between invasive and non-invasive human and
murine osteosarcoma cell lines. Although there was variation in large and small cell
volume in metastatic osteosarcoma cells, highly metastatic cancer cells exhibited
significantly smaller mean cell area and volumes compared to less metastatic cancer cells21.
These results were the first observation of the relationship between cancer cell volume and
metastatic efficiency. Therefore, it is conceivable that metastatic cancer cells require a
certain level of cell volume reduction to maneuver extravasation more efficiently. The
strong correlation between EV release and cancer cell volume reduction in my studies
showed that excessive reduction of cancer cell volume is significantly detrimental to
metastatic efficiency. My studies also identified that MLKL-mediated necroptosis
significantly increases cancer cell EV release, which can further decrease cancer cell
metastatic efficiency. Therefore, my findings implicate MLKL-mediated necroptosis as a
novel target to stop invasive cell metastasis.
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4.2.2
4.2.2.1

Future directions in the role of cancer cell morphology
change and necroptotic cancer cell death
Elucidating ESCRT-III complex participation in necroptosisinduced EV release

In chapter 4, I have shown that DMF significantly increased both MLKL and
phosphorylated MLKL levels in PC-3 cells. DMF also increased EV release in vitro and in
vivo. These results suggest that MLKL may be involved in necroptosis activation as well
as EV release. Gong et al. showed that phosphorylated MLKL translocated to the plasma
membrane and ESCRT-III complex was recruited to the site of MLKL oligomer
recruitment, resulting in shedding EVs22. Therefore, one future direction may be to
elucidate whether the ESCRT-III complex is also recruited by necroptosis induced by
DMF. To test this, PC-3 cells may be treated with DMF, and the levels of CHMP2B and
CHMP4B expression may be assessed. High resolution imaging may also be utilized to
show ESCRT-III complex at the site of EV release. This proposed study will elucidate
whether DMF-induced necroptosis also shares a common MLKL and ESCRT-III-derived
EV biogenesis mechanism.

4.2.2.2

RNAseq and proteomic analysis of DMF treated PC-3 cells

I have used DMF as a potential inducer of necroptosis. Although DMF showed a significant
increase in both MLKL and phosphorylated MLKL, it is important to elucidate the
downstream gene expression profile for two reasons. First, this profile may uncover new
downstream pathways to target in cancer cells. Second, the results may generate
fundamental insight into necroptosis. To achieve these goals, we could expose PC-3 cells
to DMF and perform RNA sequencing. We can also compare RNA sequencing data of
control and MLKL-silenced PC-3 cells exposed to DMF to confirm changes in the
expression of downstream genes.
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4.2.2.3

Investigating molecular pathways involved in cancer cell
volume reduction

Although Lyons et al. introduced the relationship between small cancer cell volume and a
higher degree of invasiveness, the underlying mechanisms of cancer cell volume reduction
during extravasation are still elusive21. McGrail et al. showed that solid tumors derived
from MCF7 breast cancer cells resist compressive stress from the tissue environment by
increasing sodium efflux and actin polymerization, and preventing cell death23,24. One
potential study to offer greater insight may focus on determining whether cancer cell
volume change is dependent on modulating tonicity and osmotic pressure. Stably
transfected PC-3 cells with a vector expressing GFP-tagged NHE1 (sodium-hydrogen
antiporter 1) and exposure to DMF may be utilized to achieve this goal. One could study
whether DMF increases the expression of NHE1 and induces cell volume changes in vitro.
Osmotic stressors may also be investigated in this platform. This study may add to the
underlying cellular process during necroptosis that regulates EV release.
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